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Abstract / Zusammenfassung 
Foot-and-mouth disease virus (FMDV) is a member of the picornavirus family, 
consisting of small non-enveloped icosahedral viruses with an RNA genome of positive 
sense. The family contains twelve different genera, including important human and 
animal pathogens. The RNA genome encodes one large open reading frame from which 
a single polyprotein is translated. This single polyprotein is processed by viral proteases 
resulting in mature viral proteins.  
The papain-like leader protease (Lbpro) of FMDV performs the initial cleavage on 
the polyprotein between its own C-terminus and the N-terminus of the structural protein 
VP4. This cleavage has been shown to be favored in cis (intramolecular), although also 
trans (intermolecular) cleavage is observed in vitro. However, intramolecular processing 
is preferred in vivo. The only other substrates cleaved by Lbpro besides the viral 
polyprotein are the two homologues of the host cell eukaryotic translation initiation factor 
4G (eIF4GI and eIF4GII). eIF4G is crucial for translation initiation acting as a scaffold 
and bringing the components of the translation initiation complex in close proximity. 
Once eIF4G is cleaved by Lbpro, it loses this property. Consequently, the protein 
synthesis of the cell is inhibited as the recruitment of capped mRNAs to the 40S 
ribosomal subunit is no longer possible. However, viral translation is unaffected as it 
initiates via an internal ribosomal entry segment (IRES) present on the 5’ untranslated 
region of the viral genome. Therefore, the virus is still able to exploit the host cell 
translation machinery.  
Lbpro is a cysteine protease with a very narrow substrate specificity mainly 
determined by the S2 pocket. Only leucine, valine and, to a certain extent, isoleucine are 
accepted at this site. The cleaved sequences on the viral polyprotein and eIF4GI both 
contain leucine at S2, whereas valine occupies this position in eIF4GII. Despite these 
constraints, no consensus sequence can be determined as the sites differ strongly from 
each other. Recently, it has been shown that especially one residue involved in the 
formation of the hydrophobic S2 pocket is of great importance for the maintenance of the 
proteases specificity. Molecular modeling and mutational analysis demonstrated that 
Leu143 is able to discriminate a substrate containing phenylalanine at the P2 position. 
Thus, a Leu143Ala variant of Lbpro was able to accept phenylalanine. Therefore, sterical 
hindrances caused by leucine might be the reason for this discrimination. The only other 
residue found at position 143 in Lbpro of different FMDV strains is methionine. Hence, the 
presence of either leucine or methionine at position 143 of Lbpro is crucial for the high 
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specificity of the protease. Furthermore, the ability to cleave substrates containing 
phenylalanine at P2 seems to be of biological relevance for the virus.  
This thesis compares the substrate specificity of Lbpro wt with the altered specificity 
of Lbpro L143A. To demonstrate the change in specificity, an eIF4GII fragment containing 
the Lbpro and eIF4E binding sequence was used as substrate. As expected, Lbpro wt 
generated only two cleavage products whereas Lbpro L143A produced additional 
cleavage products. A sequence related to the cleavage sequence of Lbpro on eIF4GII is 
not recognized by Lbpro wt due to the presence of aspartic acid at P3 and phenylalanine 
at P2. As Lbpro L143A was shown to accept phenylalanine at P2, we speculated that this 
related sequence might be cleaved as well. However, mass spectrometry analysis of two 
aberrant cleavage products gave no explicit indication that this sequence is indeed 
recognized.  
Further investigations on the specificity included the eukaryotic translation initiation 
factor 4E (eIF4E). eIF4E binds capped cellular mRNAs and the N-terminal region of 
eIF4G. Previous experiments demonstrated that upon binding of eIF4E, eIF4G 
undergoes an unfolded-to-folded transition. As a result, the eIF4G cleavage sequence is 
exposed and becomes better accessible for Lbpro enhancing the cleavage efficiency. 
However, in our in vitro approach adding different amounts of eIF4E to eIF4GII prior to 
cleavage did not change the efficiency of cleavage by Lbpro wt or Lbpro L143A.  
In a last set of experiments, a second substrate, eIF4GIIself, was used. In eIF4GIIself 
the natural cleavage sequence is exchanged with the Lbpro self-processing site. Despite 
the different chemical environment in eIF4GII than found in the viral polyprotein, Lbpro wt 
and Lbpro L143A were able to process eIF4GIIself. Furthermore, a lower amount of 
protease was needed to process 50% of eIF4GIIself compared to eIF4GII. These findings 
suggest that the self-processing sequence is, in spite of the changed chemical 
environment better recognized by Lbpro than the natural sequence of eIF4GII.  
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Der Maul-und-Klauenseuche-Virus (FMDV) gehört zur Familie der Picornaviridae. 
Diese umfasst kleine Viren ohne Lipidhülle, mit ikosaedrischem Kapsid sowie einem 
Genom positiver Polarität. Die Familie der Picronaviridae kann in zwölf verschiedene 
Genera unterteilt werden, welche sowohl für den Menschen als auch für Tiere wichtige 
Pathogene enthalten. Das RNA Genom besteht aus einem offenen Leserahmen von 
dem ein einziges Polyprotein abgelesen wird. Dieses wird anschließend von viralen 
Proteasen prozessiert.  
Die Papain-ähnliche Leader Protease (Lbpro) des Maul-und-Klauenseuche-Virus 
spaltet das Polyprotein zunächst zwischen dem eigenen C-terminus und dem N-terminus 
des strukturellen Proteins VP4. Es wurde gezeigt, dass diese Reaktion in cis 
(intramolekular) bevorzugt wird allerdings auch in trans (intermolekular) stattfinden kann. 
In vivo wird allerdings die intramolekulare Reaktion favorisiert. Neben dem viralen 
Polyprotein spaltet Lbpro die zwei Homologen des eukaryotischen Initiationsfaktor 4G 
(eIF4GI und eIF4GII) der Wirtszelle. eIF4G spielt eine zentrale Rolle während der 
Translationsinitation und sorgt als Verbindungsprotein für den Zusammenhalt der 
einzelnen Komponenten des Translationsinitationskomplexes. Sobald eIF4G von Lbpro 
gespalten wird, zerfällt dieser Komplex und die Wirtszelle kann keine gecappte mRNA 
zur 40S Untereinheit rekrutieren. Dadurch wird die Proteinsynthese der Wirtszelle 
verhindert. Die virale Translation hingegen ist nicht betroffen, da der Virus über ein 
sogenanntes internes ribosomales Eintrittssegment (IRES) initiiert. Infolgedessen 
übernimmt der Virus die Kontrolle über die Translationsmaschine der Wirtszelle.  
Lbpro ist eine Cysteinprotease mit einer stark eingeschränkten Substratspezifität, 
welche hauptsächlich von der S2 Tasche bestimmt wird. Ausschließlich Leucin, Valin 
sowie in gewissem Ausmaß werden an dieser Stelle akzeptiert. Die Sequenz bei der 
Lbpro das viral Polyprotein und eIF4GI spaltet enthält Leucin an dieser Stelle, 
wohingegen Valin diese Position in eIF4GII besetzt. Eine Konsensussequenz kann trotz 
dieser Übereinstimmung nicht festgelegt werden, da die einzelnen Sequenzen zu stark 
variieren. Vor Kurzem wurde gezeigt, dass eine weitere Aminosäure der 
hydrophobischen S2 Tasche äußerst wichtig ist für die Aufrechterhaltung der Spezifität 
von Lbpro. Molekulardesign und Mutationsanalysen ergaben, dass Leu143 ein wichtiger 
Faktor ist um Substrate welche Phenylalanin an Position P2 enthalten auszuschließen. 
Die Mutation Leu143Ala ermöglichte hingegen das Eindringen von Phenylalanin in die S2 
Tasche. Folglich dürften sterische Hinderungen der Grund für die Diskriminierung von 
Phenylalanin sein. Die einzig andere Aminosäure die an der Position 143 in anderen 
FMDV Stämmen gefunden wurde ist nur Methionin. Demnach sind Leucin oder 
Methionin an Position 143 von biologischer Relevanz um jegliche Substrate mit Phe an 
Position P2 auszuschließen.  
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Diese Diplomarbeit vergleicht die Substratspezifität des Wildtyps (Lbpro wt) mit der 
veränderten Spezifität von Lbpro L143A. Um den Unterschied aufzuzeigen wurde ein 
eIF4GII Fragment als Substrat verwendet. Dieses enthält sowohl die Lbpro Spaltsequenz 
als auch die eIF4E Bindungssequenz. Erwartungsgemäß wurden mit Lbpro wt nur zwei 
Spaltprodukte erhalten, wohingegen Lbpro L143A zusätzliche Spaltprodukte produziert. 
Eine Sequenz ähnlich jener die Lbpro in eIF4GII erkennt, wird allerdings nicht von Lbpro wt 
gespalten. Diese verwandte Sequenz wird aufgrund von Asp an Position P3 und Phe an 
Position P2 nicht erkannt. Da Lbpro L143A Phe an Position P2 akzeptieren kann, 
vermuteten wir, dass auch die ähnliche Sequenz geschnitten wird. Mittels 
Massenspektrometrie wurden zwei abweichende Spaltprodukte untersucht. Allerdings 
konnte nicht eindeutig bewiesen werden, dass Lbpro L143A diese Sequenz erkennt. 
Desweiteren wurde bei späteren Experimenten zusätzlich der eukaryotische 
Initiationsfaktor 4E (eIF4E) eingesetzt. eIF4E bindet einerseits zelluläre gecappte 
mRNAs, andererseits aber auch die N-terminale Region von eIF4G. Vorangehende 
Experimente haben gezeigt, dass eIF4G von einer ungeordneten in eine geordnete 
Konformation übergeht sobald es an eIF4E bindet. Dadurch wird die Region der 
Spaltung vermutlich stärker exponiert und ist für Lbpro leichter zugänglich. Dies wiederum 
sollte zu einer verbesserten Prozessierung durch Lbpro führen. Allerdings konnte bei 
meinem in vitro Versuchen keine Effizienzsteigerung durch den Zusatz von eIF4E zu 
eIF4G und anschließender Zugabe der Protease beobachtet werden.  
Abgesehen von eIF4GII wurde ein weiteres Substrat verwendet, nämlich eIF4GIIself. 
eIF4GIIself enthält die Selbstprozessierungssequenz von Lbpro statt der natürlichen 
Spaltungssequenz. Obwohl die chemische Umgebung in eIF4GII eine andere ist als jene 
im viralen Polyprotein, schneiden beide Proteasen (Lbpro wt und Lbpro L143A) die 
Selbstprozessierungssequenz. Überdies werden 50% eIF4GIIself bereits bei einer 
geringeren Menge an Protease geschnitten als eIF4GII. Folgedessen könnte man 
annehmen, dass Lbpro die Selbstprozessierungssequenz mit größerer Effizienz erkannt 
wird als die natürliche Sequenz in eIF4GII.   
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1 Introduction 
1.1 Picornaviruses 
The family of Picornaviridae belongs to the order of Picornavirales and consists of 
twelve different genera. Viruses of these twelve genera infect vertebrates and include 
important human and animal pathogens such as hepatitis A virus (HAV), human 
rhinovirus (HRV), poliovirus (PV) and foot-and-mouth disease virus (FMDV) (ICTV 2009). 
Picornaviruses are non-enveloped, single stranded RNA viruses of positive sense. 
The virions are spherical and about 30 nm in diameter. The particles are constructed in a 
simple way, consisting of an icosahedral protein shell which surrounds the naked RNA 
genome (Fields et al. 2007).  
 
1.2 Foot-and mouth disease virus 
Foot-and-mouth disease virus (FMDV) together with bovine rhinitis B virus and 
equine rhinitis A virus constitute the genus aphthovirus of the picornavirus family (ICTV 
2009). Seven serotypes (A, O, C, Asia 1 and South African Territories 1, 2 and 3) of 
FMDV have been identified, each occurring in several subtypes. FMDV is the causative 
agent of foot-and-mouth disease, a highly infectious viral disease affecting wild and 
domestic cloven-hoofed animals such as cattle, swine and sheep (Fenner et al. 1993). 
FMDV is transmitted via direct contact between animals, by animal products (milk, meat 
and semen) and via the airborne route. The symptoms include vesicular lesions on 
tongue, feet, snout and teats, fever and lameness. The mortality rates in adult animals 
are quite low, whereas in young animals the virus affects the heart and may lead to 
higher lethality.  
Foot-and-mouth disease was first described in the 16th century (Fracastorius 
1546). 400 years later it was the first animal pathogen identified as a virus (Loeffler et 
al.1897) and is therefore, besides poliovirus, one of the best-studied viruses. Major 
outbreaks of FMDV have occurred in nearly all livestock-containing regions except New 
Zealand and always caused great expense.  
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1.3 The virion 
1.3.1 Genome organization  
The genetic information of picornaviruses is encoded on a single-stranded RNA 
genome of positive polarity, containing only one open reading frame (ORF) (Fields et al. 
2007). The FMDV genome contains untranslated regions (UTRs) downstream and 
upstream of the ORF.  
The 5’-UTR, presented in figure 1, is about 1.300 bases and highly structured 
(Belsham et al. 2004). It contains five different elements involved in viral translation and 
RNA replication. The S-fragment is the most 5’ element and folds into a stem-loop. Its 
function in the FMDV genome has not yet been determined. However, comparisons with 
other picornaviruses imply that it might be involved in genome stability in infected cells 
(Barton et al. 2001) and in the binding of proteins during genome replication (Andino et 
al. 1990, Andino et al. 1993, Herold et al. 2001). A poly(C) tract of about 100 bases 
follows the S-segment. The length of this element can vary strongly, but its exact 
function is still unknown (Rieder et al. 1993). Downstream of the poly(C) tract lies a 
series of RNA pseudoknots of unknown function (Escarmis et al. 1995) followed by a 
hairpin loop structure, the cis-acting replicative element (cre) (Mason et al. 2002). The 
cre element consists of a stem loop containing a conserved AAACA sequence and is 
crucial for RNA genome replication. The cre is located within different regions of the ORF 
in other picornavirus species, whereas in FMDV it is found in the 5’ UTR. Between the 
cre and the ORF region, a series of highly conserved stem loops build the internal 
ribosome entry site (IRES). Picornaviral mRNAs lack the 7-methylguanosine cap 
structure, present in most eukaryotic mRNAs. Thus, ribosomes enter the genome 
internally at the IRES (Niepmann et al. 1997). The IRES region of aphthoviruses is about 
450 nucleotides in length controlling the translation of the viral RNA (Macejak et al. 1991, 
Belsham et al. 1990, Kuhn et al. 1990). One of the five domains of the IRES (Pilipenko et 
al. 1992b) is a pyrimidine-rich region located at its 3’ end, directly before the AUG 
initiation codon. At the very 5’ end, the viral protein VPg (viral protein, genome linked) is 
covalently bound to the picornaviral RNA genome (Paul et al. 2003) and possibly primes 
RNA synthesis (Gerber et al. 2001).   
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The 3’-UTR, which follows the ORF, is much shorter and contains a stretch of RNA 
forming stem-loop structures (Pilipenko et al. 1992a) followed by a poly(A) tail (Serrano 
et al. 2006). The 3’ UTR may be essential for genome replication (Melchers et al. 1997, 
Pilipenko et al. 1996, Rohll et al. 1995). This hypothesis is supported by the fact that 
several picornaviral proteins involved in RNA replication bind to this region (Cui et al. 
1993, Cui et al. 1995, Harris et al. 1994). Furthermore, studies demonstrated that 
deletion of the FMDV 3’ UTR reduces efficiency of the viral in vitro translation (Lopez de 
Quinto et al. 2002). The poly(A) tail is thought to be crucial for translation as well as RNA 
replication (Barton et al. 2001, Herold et al. 2001).  
 
 
Figure 1: Schematic representation of the FMDV RNA genome focusing on the 5` and 3’ 
UTRs.  (Vagnozzi et al. 2007) 
The single ORF itself is organized in four regions, L and P1-P3 (figure 2). The L 
region encodes two alternative AUG initiation codons. Therefore, the translation results 
in two different forms of the L protein, Lab and Lb (Carrillo et al. 2005). Lab (20 kDa) 
being the protein produced by initiation from the first AUG codon, and Lb (16 kDa) from 
the second AUG. Data suggests that Lb is the biologically functional protein in vivo 
(Piccone et al. 1995).  
The L region is followed by the P1 region encoding the four structural proteins, viral 
protein 1 (VP1)-VP4. The P2 and P3 region, on the contrary, code for non-structural 
proteins. P2 is coding for 2A, 2B and 2C. In FMDV the 2A protein has no proteolytic 
activity in contrast to other picornavirus species such as HRV and PV (Donnelly et al. 
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2001). However, a separation event occurs at the N-terminus of the 2A protein and the 
C-terminus of VP1 which is due to a proposed ribosomal skip (de Felipe et al. 2003). P3 
encodes 3A, 3B, 3Cpro and 3Dpol. 3Cpro and its precursor 3CDpro have been identified as 
viral proteases (Birtley et al. 2005) that process the viral polyprotein. However, 3Dpol is a 
RNA-dependent RNA polymerase (Ferrer-Orta et al. 2003).  
 
Figure 2: Organization of the FMDV RNA genome. The open boxes indicate the ORF and the 
viral proteins. The partial cleavage products are shown at the bottom. RNA structures of the 5’ 
and 3’ UTRs are shown as lines (adapted from Mason et al. 2003).  
 
1.3.2 Capsid organization 
The picornaviral capsid consists of 60 protomers that are tightly packed to form 
an icosahedron (figure 3a). Each protomer contains one copy of viral protein 1 (VP1) - 
VP4 (figure 3b). VP1, VP2 and VP3 build the outer surface whereas VP4 is located on 
the inner surface of the capsid (Fields et al. 2007). Even though the structural proteins 
VP1-VP3 have no sequence homology, they share the same topology. All three fold into 
an eight-stranded wedge-shaped ß-barrel (Burke et al. 1991). The strands of the β-barrel 
are connected by loops.  
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Figure 3: Structure of the picornaviral protomer and capsid. (a) Schematic view of an 
icosahedral capsid, showing the organization of the protomers (expasy.org). (b) Structure of the 
mature type O1BFS FMD virion based on X-ray crystallography. A viral protomer showing β-
barrel-and-loop organization of VP1-VP4 and their location on the virion (Grubman et al. 2004).  
The first structure of a picornaviral capsid was that of HRV14 (Rossmann et al. 
1985). Several cryo-EM or X-ray crystal structures followed (e.g. for FMDV serotype O 
(Acharya et al. 1989) and PV1 (Hogle et al. 1985)). All structures revealed that all 
picornaviral capsids have an icosahedral symmetry with a triangulation number of T=3. 
The arrangement of VP1-VP3 gives rise to an uneven surface with a star-shaped plateau 
at the fivefold axis, surrounded by a deep depression (canyons) and another protrusion 
at the threefold axis (Fields et al. 2007). This canyon is normally referred to as the 
receptor binding site for entero- and cardioviruses but is not found on the surface of 
FMDV (Acharya et al. 1989). Another unique feature of FMDV is the presence of a pore 
at the five-fold axis, which allows small molecules to enter (Jackson et al. 2003). In 
contrary to some picornavirus species, the FMDV capsid dissociates at low pH and 
cannot pass the intestinal tract as the acid stable poliovirus or certain enteroviruses.   
 
1.4 Life Cycle 
1.4.1 Attachment and cell entry 
Studies by Moore and Cowan (Moore et al. 1987) showed that trypsin treatment 
of FMDV results in noninfectious viral particles due to their inability to attach to cells. 
Further experiments revealed that trypsin cleaves VP1 at position Arg144 (Robertson et 
al. 1983), which suggests that the region around Arg144 might interact with the cell 
surface receptor. Subsequent studies on the binding of fibronectin to cells revealed the 
tri-peptide sequence Arg-Gly-Asp (RGD) as the cellular recognition site for the 
fibronectin-receptor (Pierschbacher et al. 1984). This sequence is also found in FMDV 
VP1 (Burman et al. 2006) and shown to be highly conserved amongst differend FMDV 
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strains (Pfaff et al. 1988). The fibronectin-receptor belongs to the integrin family (Baxt et 
al. 1990) and consist of two subunits (α and β) that are bound at the cell surface. To 
confirm the interaction between the conserved sequence and the receptor, small 
peptides containing RGD were used to inhibit the binding of virus to the cells (Baxt et al. 
1990, Fox et al. 1989). Site directed mutagenesis of the RDG sequence led to 
noninfectious viral particles, thus verifying former findings (Leippert et al. 1997, Mason et 
al. 1994, McKenna et al. 1995). αVα3 integrin was the first receptor identified to bind 
FMDV (Berinstein et al. 1995). However, it has been demonstrated that FMDV can also 
interact with αVα6 (Jackson et al. 2000) and αVα1 (Jackson et al. 2002). Certain FMDV 
strains also use heparan sulfate as cellular receptor (Jackson et al. 1996).  
The exact process of entry and uncoating of FMDV is still vague but Carrillo et al. 
(Carrillo et al. 1985, Baxt et al. 1987) suggest a breakdown of the virion into subunits 
upon entry of acidic endosomes.  
 
1.4.2 Translation and processing of the viral polyprotein 
Replication of picornaviruses occurs entirely in the cell cytoplasm (figure 4). 
Following uncoating of the viral particle, the RNA is released into the cytoplasm. As 
picornaviruses are single-stranded positive sense RNA viruses, viral RNA serves as 
mRNA in the host cell. Picornaviral RNA cannot be copied by any cellular RNA 
polymerase and the viral capsid does not carry any viral enzymes. Therefore, 
picornaviral translation needs to occur before RNA replication (Fields et al. 2007). In 
contrary to host mRNA, viral mRNA does not contain a 7-methylguanosine cap at the 5’ 
end (Martínez-Salas et al. 1999) and initiates protein synthesis internally at the IRES via 
a cap-independent mechanism (Belsham et al. 1990). As only one ORF is found on 
picornaviral genomes, translation results in the production of a single polyprotein. This 
polyprotein undergoes a series of cleavages producing structural and non-structural 
proteins (figure 1). Due to co-translational processing, no polyprotein is observed in 
infected cells (Fields et al. 2007). 
The cleavage reactions are performed by two virally encoded proteases, Lbpro and 3Cpro. 
The cascade of cleavages is initiated by Lbpro, which cleaves between its own C-terminus 
and the N-terminus of VP4 (figure 2) (Guarné et al.1998). The 2A protein of FMDV, an 
18 amino-acid peptide, has no proteolytic activity. Nevertheless, the polyprotein is 
processed between the C-terminus of 2A and the N-terminus of 2B. A putative ribosomal 
skip was proposed as the mechanism that causes the interruption of the polyprotein 
chain (de Felipe et al. 2003). All remaining cleavages are performed by 3Cpro or its 
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precursor 3CDpro. 3Cpro and its precursor cleave at dipeptide sequences as Gln-Gly, Glu-
Gly, Gln-Leu and Glu-Ser (Birtley et al. 2005).  
 The last processing event is the maturation cleavage of VP0 into VP4 and VP2 in 
the already assembled viral particle. This process is thought to be autocatalytic requiring 
the presence of viral RNA and a conserved histidine in VP2 that initiates the nucleophilic 
attack (Basavappa et al. 1994, Curry et al. 1997, Hindiyeh et al. 1999).  
 
 
Figure 4: Schematic overview of the picornaviral life cycle. Virus attaches to a host receptor 
and enters the cell (1). After uncoating, the viral genomic RNA is released and VPg is removed 
from the RNA (2). RNA is first translated into a single polyprotein (3) that is co-translationally 
cleaved into viral proteins (4). RNA replication is carried out at membranous vesicles where the 
minus strand intermediate is synthesized by 3Dpol (5). This intermediate is used to produce new 
plus strand RNAs (6), which are packed into the viral particles (8) and released after maturation 
cleavage by lysis (9) (Fields et al. 2007).  
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1.4.3 Genome replication 
Besides protein synthesis, the viral RNA is used as template for viral replication. 
Thus, due to this double function the viral genome needs to be recognized by the cellular 
translation machinery and the viral replication apparatus (Herold et al. 2001). Even 
though this process has been studied in other picornaviruses than FMDV, most of it is 
proposed to be similar (Paul et al. 2002). Picornaviral genome replication is a highly 
extensive process including all viral proteins except the structural ones. Evidence 
indicates that also host cell proteins are essential for picornaviral replication (Diez et al. 
2000). A certain critical concentration of 3CDpro is thought to initiate the shift between 
translation and transcription, as those two processes do not occur simultaneously 
(Gamarnik et al. 1998, Barton et al. 1999). Accumulated 3CDpro then binds to the 5’ 
cloverleaf structure and promotes transcription. Whether this mechanism proceeds 
similarly in FMDV is unknown. However, in FMDV infected cells 3CDpro is rapidly cleaved 
into 3Cpro and 3Dpol (Fields et al. 2007) which would argue against it.    
Picornaviral RNA replication occurs in the cytoplasm at virus induced vesicles 
derived from membranes of the endoplasmatic reticulum and the Golgi apparatus 
(Monaghan et al. 2004). RNA synthesis of the negative strand is initiated at the 3’ end of 
positive stranded RNA viruses. In picornaviruses, the 3’ poly(A) tail is proposed to 
participate in RNA replication (Herold et al. 2001).  Furthermore, Herold et al. 
demonstrated that ribonucleoprotein (RNP) complexes formed at the 3’ and 5’ ends of 
genomic RNA interact via a protein bridge. This interaction of the RNP complexes is 
thought to cause the circularization of the viral genome and thus be essential for the 
translation initiation of negative sense viral RNA (figure 5).  
Following the initiation, the viral RNA dependent RNA polymerase 3Dpol 
synthesizes a minus strand RNA intermediate. As 3Dpol is a primer-dependent enzyme, it 
is not able to initiate RNA synthesis on a naked RNA strand. VPg is thought to be 
involved in the initiation of RNA replication by priming 3Dpol (Paul et al. 2003).  
The generated minus strand forms fully double stranded RNA replication 
intermediates, the replicative form, which serve as template for the production of large 
excess of positive stranded RNA (Lescar et al. 2009).  
Several secondary structure elements of the viral RNA are also involved in 
picornaviral replication. The cloverleaf at the 5’ UTR (Andino et al. 1990) and a stem loop 
in the 3’ UTR (Pilipenko et al. 1992a) assure correct recruitment of the viral RNA to the 
replicative complex. 
 
 15 
 
Figure 5: Model of translation initiation of negative strand RNA synthesis in poliovirus 
replication. After the translation, the viral polymerase precursor 3CD binds together with poly(A) 
binding protein (PABP) and the cellular factor poly(rC) binding protein (PCBP – a component of 
the RNP complex) to the 5’ cloverleaf structure. These interactions bring the viral polymerase in 
close proximity to the 3’ poly(A) tail thus initiating translation (Herold et al. 2001).  
 The cis replicative element (cre), a stem loop found in the 5’ UTR of FMDV, 
contains a conserved AAACA motif within the loop. Cre functions as template for the 
uridylylation of VPg to generate VPgpUpUOH (Steil et al. 2009). This is feasible because 
of the presence of two adenosine residues in the loop of the cre that allow the viral RNA-
dependent RNA polymerase 3Dpol to add two uridine residues to the tyrosine residue of 
VPg. VPg and VPgpUpOH function as primer for the the RNA-dependent RNA 
polymerase 3Dpol (Steil et al. 2009). Although, the cre element has similar functions in 
different picornaviruses, it is located in distinct regions of the genome. The cre sequence 
of poliovirus was found in the protein-coding region of the 2C protein (Goodfellow et al. 
2000) while in human rhinovirus 14 the cre sequence is encoded in the P1 region 
(McKnight et al. 1998).  
 
1.4.4 Assembly and release of the virus 
The final steps of the viral life cycle are the encapsidation of newly synthesized 
plus stranded RNA linked to VPg (Novak et al. 1991) and the maturation cleavage of 
VP0 into VP2 and VP4. The building blocks of the capsid are protomers, which contain 
one copy of VP0, VP1 and VP3. Five protomers (5S) can assemble to form a pentamer 
(14S), of which 12 are used to form the final capsid structure. Currently, there are two 
modes of assembly. One suggests the formation of empty capsids (80S) into which RNA 
is inserted subsequently (Jacobson et al. 1968). The second proposes that pentamers 
directly interact with the RNA, forming the provirion (150S) (Nugent et al. 1995; figure 6). 
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In presence of viral RNA, VP0 is cleaved into VP2 and VP4 resulting in the mature virion 
(160S) (Basavappa et al. 1994).   
 
 
Figure 6: Assembly of the viral particle. Five protomers are combined to form the 5S subunit 
that further builds the 14S pentamer. Two mechanisms are possible: the internalization of the 
RNA, after formation of the 80S capsid or the direct interaction of the 14S pentamers with the 
RNA giving rise to the provirion. The maturation cleavage of VP0 into VP4 and VP2 yields mature 
160S virions. (Rotbart et al. 1995) 
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1.5 Leader protease (Lbpro) 
The proteolytic activity of the leader protein is a specific feature of aphtho- and 
erboviruses. It is encoded at the very 5’ end of the genome and represents the second 
protease besides 3Cpro. Initiation of protein synthesis can start at two different AUG start 
codons lying 84 nucleotides apart (Carrillo et al. 2005). Translation gives rise to two 
species of the leader protein, Labpro and Lbpro. Both variants display the same enzymatic 
properties, even though Lbpro is 28 amino acids (aa) shorter than Labpro. Throughout this 
work Lbpro of FMDV O1k was used, as it was shown that it is the physiologically active 
protease (Cao et al. 1995).  
 
1.5.1 Structure of Lbpro 
Lbpro was found to be a cysteine protease possesing a papain-like fold (Guarné et 
al. 1998). Even though papain and Lbpro share only 15% of sequence identity, the 
residues of the active site are conserved. Figure 7 shows the X-ray crystal structures of 
Lbpro and papain. Both consist of a compact globular domain organized in two 
subdomains with the active site residues Cys51 and His148 of Lbpro and Cys25 and 
His159 of papain at the interface of the N-terminal and C-terminal domain. The N-
terminal domain of Lbpro contains four α-helices (α1-α4) and two short antiparallel β-
strands (β1 and β2). The nucleophilic Cys51 is located at the N-terminal end of α1 which 
runs perpendicularly to α3. The C-terminal subdomain represents a fold composed of 
only mixed β-sheets, one parallel (β3-β4) and six antiparallel (β4-β9) β-strands. His148 is 
located at the connecting turn of β5 and β6. In Lbpro, the catalytic triad is completed by the 
conserved Asp163, which keeps Cys51 and His148 in the correct orientation to each 
other. Asparagine completes the catalytic triad in papain (Guarné et al. 2000).   
Despite the similarity to papain, Lbpro contains 18 aa protruding from the globular 
domain, with no equivalent in papain. This long C-terminal extension (CTE) is a highly 
flexible region involved in self-processing and the cleavage of eukaryotic initiation factor 
4G (eIF4G) (Glaser et al. 2001, Cencic et al. 2007). Cencic et al. showed that a version 
of Lbpro with a shortened CTE was not able to self-process. Another unusual property of 
the CTE is its insertion into the active site of the neighboring molecule giving rise to a 
stable homodimer (Guarné et al. 1998). Residues Lys201 and Leu200 of the CTE, at 
position P1 and P2, provide strong interactions with the substrate-binding site (The 
nomenclature of the binding and corresponding cleavage sites on the enzyme is that 
from Berger and Schechter 1970).  
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Figure 7: Crystal structures of (a) Lbpro (Guarné et al. 1998) and (b) papain (Kamphuis et al. 
1984). α - helices and β-sheets are shown in green and purple, respectively. The residues of the 
active site are represented as yellow sticks. For crystallization, Cys51 of Lbpro was mutated to Ala 
(C51A). In papain, the active Cys25 was mutated to cysteinesulfonic acid (C25CSA). The 18 aa 
CTE of Lbpro is depicted in red. Created with PyMOL (Delano, 2002) using the PDB ID codes 
1QOL (a) and 9PAP (b).  
Residues P1 to P3 are bound to the active site in an extended conformation whilst 
P4 to P7 are bound in a tight turn comparable to a 310 α-helix (Santos et al. 2009).  
The S1 subsite forms a narrow cleft which prefers a basic residue at the P1 
position. In Lbpro Lys201 (P1) points away from the active site and is embedded between 
residues Glu96 and Glu147. The side chains of other residues tested at this position 
clashed with the aliphatic side chains of these glutamates and were thus not accepted.  
As in other cysteine proteases (e.g. papain), the specificity of Lbpro is mainly 
determined at the S2 position. Therefore, only leucine, valine and, to a certain extent, 
isoleucine, are accepted (Santos et al. 2009). Figure 8 shows that Leu200 (P2) is 
completely buried in the deep cavity formed by several hydrophobic residues (side chain 
resdiues P99, P100, A101, I141, L143, A149 and L178 and the main-chain atoms of 
W52, F142, and H148). Kuehnel et al. suggested that Lbpro is able to discriminate 
between Leu and Phe at the P2 position and can also exclude acidic residues at P3. 
Especially the P2 Leu200 to Phe substitution affected self-processing (Kuehnel et al. 
2004). Subsequently, Mayer and colleagues (Mayer et al. 2008) examined the S2 pocket 
for residues which might clash with Phe at P2. Molecular modeling experiments showed 
that the side chain of Leu143 might prevent the binding of Phe. Therefore, leucine was 
replaced by the smaller side chain of alanine to test whether this would improve the 
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acceptance of Phe. An additional Leu143 to Ala substitution in a Leu200Phe variant 
restores the self-processing event. As alanine provides more space in the S2 pocket, 
sterical hindrances caused by Leu143 could be the reason for the exclusion of Phe. 
Sequence alignments revealed that Leu143 is not invariant, but the only other residue 
occurring at this position is methionine, another hydrophobic residue with a bulky side 
chain (Mayer et al. 2008).  
 
Figure 8: The structure of the S2 pocket of Lbpro. (a) Structure of the wild-type S2 pocket 
showing Leu200. (b) Leu200 has been substituted to Phe by molecular modeling. The residues of 
the hydrophobic pocket are presented in dark green. The backbone of the CTE and Leu200 
shown in yellow. Active site residues are shown in red (Cys51 is replaced by Ala in the crystal 
structure). Main chain interactions contributing to the formation of the S2 pocket are in light-green 
(Mayer et al. 2008).  
Hence, Leu143 seems to be important for the maintenance of the Lbpro specificity 
as especially substrates with phenylalanine at the P2 residues are not processed. The 
number of possible substrates is therefore restricted, which is supported by the fact that 
besides the two homologues of eIF4G and the viral polyprotein (Santos et al. 2009), no 
other substrate has been identified. Furthermore, the observed dimer formation might 
inhibit substrate cleavage and reduce the number of substrates even further.  
Lys199 (P3), pointing away from the substrate binding site, and Arg198 (P4) 
occupy the pockets of the S3 and S4, respectively. It was demonstrated that Asn and Lys 
are preferred at P3, whereas Asp and Arg are less favored. In contrast, Arg is accepted 
in the S4 pocket forming hydrogen bonds with Gln146 and Van der Waals interactions 
with Leu143 (Santos et al. 2009).  
Although, there is no real binding site for the P5 residue, Gln197 is possibly 
involved in the formation of the 310-turn mentioned above.  
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The site for P6 recognition is composed of several hydrophobic residues able to 
accept the wild-type Val196 as well as Phe, Pro and Ser. Lys195 at the P7 position forms 
Van der Waals interactions with Leu143.   
Additionally, some residues contribute to more than one specific pocket. Leu178 
is involved in the formation of to the S2 and the S6 pocket, whereas Leu143 is essential 
for the formation of the S2 and S4 subsite and forms Van der Waals interactions with 
Lys195 (Santos et al. 2009).  
 
1.5.2 Functions and enzymatic activities of Lbpro 
As already described above, Lbpro is a highly specific protease, cleaving only three 
known substrates. These are the viral polyprotein at the Lbpro-VP4 junction and the two 
homologues of eIF4G. Table 1 summarizes the cleavage sites recognized by Lbpro. A 
consensus sequence cannot be determined, as the cleavage sites differ strongly from 
each other.  However, the related sequence AFADFGXRQTPGG in eIF4GII is not 
cleaved by Lbpro. The presence of the aspartic acid at the P3 position or phenylalanine at 
P2 prevent the cleavage.  
Substrate    P-region  P'-region 
        
Lbpro-VP41)  VQRKLK201 ↓ 202GAGQSS 
eIF4GI2) SFANLG674 ↓ 675RTTLST 
eIF4GII3)   PLLNVG702 ↓ 703SRRSQP 
eIF4GII not cleaved4) AFADFG686 X 687RQTPGG 
 
Tabel 1: Overview of cleavage sites recognized by Lbpro. Sequences are taken from 1)Strebel et 
al. 1986,  2) Foeger et al. 2002,  3) Gradi et al. 2004 and  4)Kuehnel et al. 2004, respectively.  
 
1.5.2.1 Self-processing 
The initial cleavage event on the FMDV polyprotein occurs co-translational and is 
achieved by the Lbpro, which frees itself by cleaving between its own C-terminus and the 
N-terminus of VP4 at the sequence VQRKLK201↓202GAGQSS (Strebel et al. 1986). This 
reaction could be either intra- or intermolecular (cis or trans, respectively) (Glaser et al. 
2001).  X-ray crystal and NMR structures show the CTE bound to the active site of the 
neighboring molecule, arguing for an intermolecular self-processing event whereas 
several characteristics suggest an intramolecular reaction as molecular modeling studies 
consider the possibility of the CTE to fold back and bind to its own active site (Cencic et 
al. 2007). The high mobility of the CTE would argue for this possibility. Furthermore, 
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Glaser and colleagues already demonstrated that intramolecular self-processing and 
intermolecular cleavage of eIF4GI is favored over intermolecular self-processing and 
intramolecular cleavage of eIF4GI (Glaser et al. 2001).  
 
1.5.2.2 eIF4G binding and cleavage 
The only host cell proteins cleaved by Lbpro during FMDV infection are the 
homologues of eIF4G. This cleavage disrupts the scaffolding function of eIF4G (see 
1.6.1), leading to the inhibition of host cell protein synthesis, also termed host cell shut 
off. Viral translation, however, remains unaffected as it initiates via an IRES.  
Most of the work published on eIF4G processing was on eIF4GI. As the crucial 
characteristics are conserved, the results are transferable to a large extent.  
The cleavage of eIF4GI and eIF4GII is very effective in vivo and in vitro, but the 
concentration of Lbpro in infected cells at the time of eIF4G cleavage is much lower than 
the protease needed for in vitro experiments (Glaser et al. 2000, Kirchweger et al. 1994). 
These findings led to the suggestions that Lbpro activates latent cellular proteases 
(Wyckoff et al. 1990, Wyckoff et al. 1992). However, no such cellular protease could be 
identified. Furthermore, Ohlmann et al. suggest that the eIF4G-eIF4E complex is the 
actual substrate for Lbpro (Ohlmann et al. 1997). While 2Apro of HRV2 only interacts with 
eIF4GI when eIF4E is present, Lbpro is able to cleave eIF4G on its own. Nevertheless, 
binding of Lbpro to eIF4G is enhanced upon complex formation with eIF4E due to an 
unfolded-to-folded transition of eIF4G as observed in yeast eIF4GI (Hershey et al. 1999, 
Gross et al. 2003, Foeger et al. 2002). These rearrangements are thought to cause the 
exposure of the Lbpro cleavage sequence on eIF4G thus facilitating the accession of 
Lbpro. Therefore, the binding of eIF4E to eIF4G is considered to enhance the cleavage 
process.  
The interaction site of eIF4GI with the Lbpro is located at a distinct site away from 
the cleavage site (Table 1). Amino acids 645-657 on eIF4GI were demonstrated to act as 
the binding site for Lbpro (Foeger et al. 2005). Three basic residues (Lys643, Lys646 and 
Arg650) are conserved between human eIF4G homologues and several mammalian 
species. Foeger et al. demonstrated that substitution of any of these residues with Ala 
influences the interaction with Lbpro differently (Foeger et al. 2005). The replacement of 
Arg650 and Lys646 reduces the binding efficiency by 75% and 50-75%, respectively. In 
contrast, the substitution of Lys643 lowers the binding only by 10-20%. These results 
would imply that the three basic residues might be recognized by residues of the CTE 
thus facilitating interaction.   
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The eIF4G binding domain on Lbpro is found 25 Å distant from the active site and 
involves Cys133 and the residues 183-195 of the CTE. The two acidic residues Asp184 
and Glu186 of the CTE are conserved in all seven FMDV serotypes and play an 
important role in the binding of eIF4GI. Investigation of mutants Asp184Ala and 
Glu186Lys showed a delay of eIF4GI cleavage. Additionally, the double mutant 
Gln185ArgGlu186Lys delays eIF4GI cleavage even further. This suggests that the 
overall charge of this region might be important for eIF4GI interaction. Interestingly, 
neither of these mutations inhibits eIF4GI cleavage completely or affects Lbpro self-
processing. In contrast, Cys133 is not only involved in binding of eIF4GI but also affects 
cleavage as shown by site-directed mutagenesis (Foeger et al. 2002).  
Figure 9 represents the arrangement of Lbpro residues involved in eIF4GI 
recognition. Residues Asp184 and Glu186 are distal to the Lbpro active site and 12 Å 
from Cys133. Therefore, interactions with any residues of the globular domain or the 
CTE seem unlikely, as both residues point away from the molecule. Hence, the inhibition 
of eIF4GI cleavage is possible without affecting self-processing whereupon self-
processing is no prerequisite for eIF4G cleavage (Glaser et al. 2001).   
 
 
Figure 9: Lbpro residues involved in eIF4GI recognition. α-helices and β-sheets are shown in 
green and purple respectively. The catalytic residues C51 and H148 of Lbpro and C133, Q185, 
D184 and E186 are shown as sticks (Foeger et al. 2005). 
 
1.5.2.3 Interference of Lbpro with innate immunity 
Viruses evolved different mechanisms to overcome the early host cell immune 
response. FMDV wild-type was shown to, on the one hand, block host protein synthesis 
due to the inhibition of cap-dependent translation (Chinsangaram et al. 2001). On the 
other hand, the virus inhibits the induction of IFN-α/β mRNA (de los Santos et al. 2006). 
De los Santos and colleagues recently demonstrated that Lbpro is directly associated with 
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the regulation of IFN-β expression. Thereby, Lbpro degrades p65/ReIA, a subunit of the 
nuclear factor κB (NF-κB) (de los Santos et al. 2007). The direct involvement of Lbpro was 
demonstrated by experiments with a FMDV without the leader protease sequence which 
did not cause any degradation of P65/ReIA. Thus, the activity of NF-κB is directly 
affected which in turn is required for the expression of IFN-β. Furthermore, these 
experiments may indicate that P65/ReIA is cleaved by Lbpro (de los Santos et al. 2007). A 
putative Lbpro cleavage site was found by analyzing the amino acid sequence of 
p65/RelA. However, no degradation products could be detected which could indicate that 
p65/ReIA cleavage does not occur during FMDV infection.  
 Nevertheless, the leader protease of FMDV is crucial for the survival of the virus 
in the host cell and has evolved mechanisms to antagonize the innate immune response 
at multiple levels.  
 
1.6 Translation initiation 
1.6.1 Cap-dependent translation 
Eukaryotic cells synthesize their proteins using a cap-dependent translation 
process. The 7-methyl-guanosine cap at the 5’ end of cellular mRNAs is on the one hand 
essential for stabilization and RNA splicing. On the other hand, the cap structure recruits 
eIF4E. eIF4E then interacts with eIF4G, which recruits the 40S ribosomal subunit via 
binding the eukaryotic iniation factor 3 (eIF3) (figure 10).   
Translation is a stepwise process and starts by formation of the 43S preinitiation 
complex comprising a 40S ribosomal subunit, eukaryotic initiation factor (eIF) 1 (eIF1), 
eIF1A, eIF3, eIF2-GTP-Met-tRNAiMet and probably eIF5 (Hershey et al. 2000, Lopez-
Lastra et al. 2005). The mRNA becomes activated by attachment of the eIF4F complex, 
consisting of eIF4E, eIF4G and eIF4A. The 40S ribosomal subunit of the preinitiation 
complex then binds to the already activated mRNA and starts to unwind and scan the 
mRNA for the initiation codon (Hentze et al. 1997, Pain et al. 1996). The joining of the 
60S ribosomal subunit completes the 80S initiation complex and translation can occur.  
The eukaryotic initiation factors 4E and 4G of the eIF4F complex are especially 
relevant to this work. 
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Figure 10: Translation initiation factors involved in cap-dependent translation of 
picornaviruses. During host cell translation initiation, eIF4G acts as a scaffold bringing the 
different parts of the initiation complex together and recruting the 40S subunit to the mRNA. 
eIF4E binds the cap structure of the 5’ end of the mRNA and recruits the eIF4G (Fields et al. 
2007).  
 
1.6.1.1 Eukaryotic initiation factor 4G (eIF4G) 
eIF4G is a 220 kDa protein, formerly named p220 or eIF-4γ. Human eIF4GI was 
first isolated as part of a large protein complex which was able to restore protein 
synthesis in lysates derived from poliovirus-infected HeLa cells (Tahara et al. 1981). This 
complex was identified as translation initiation complex eIF4F, in which eIF4G acts as 
scaffold holding different components of the complex together (LeFebvre et al. 2006). 
Two homologues of human eIF4G, termed eIF4GI and eIF4GII, are known which have 
46% identity at the amino acid level and an overall similarity of 56% (Gradi et al. 1998). 
The homology is particularly high in the area of the central part where a stretch of 70 aa 
is conserved. Even though eIF4GII has a predicted molecular mass of about 176 kDa, 
both homologues migrate as a series of bands at 195 kDa when separated by SDS-
PAGE (Lamphear et al. 1995). The later identified eIF4GII is a functional homolog that 
interacts with eIF4E, eIF4A and eIF3 as does eIF4GI. Moreover, eIF4GII was found to be 
present in the eIF4F complex and therefore is vital for translation initiation. 
eIF4G consists of two domains, an N-terminal domain and a C-terminal domain. The N-
terminal domain contains a binding site for the cap binding protein eIF4E (Mader et al. 
1995) and the poly-A binding protein (PABP). Binding of the PABP leads to the 
circularization of the translation initiation complex (Imatka et al. 1998). In contrast, the C-
terminal domain interacts with eIF4A, eukaryotic initiation factor 3 (eIF3) and protein 
kinase MnkI (Pyronnet et al. 1999). Hence eIF4G is vital for translation initiation as it co-
ordinates the components required to build the preinitiation complex onto the messenger 
RNA. A schematic representation of eIF4GII is shown in figure 11.  
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Figure 11: Domains of eIF4GII. Binding sites for different proteins are colored. The blue arrow 
indicates the cleavage sites for the picornaviral proteases 2Apro and Lbpro (adapted from 
Marcotrigiano et al. 2001).  
Amino acids 605-718 were shown to be necessary for interaction of eIF4GII with 
eIF4E. This region contains the 13 conserved amino acids KQYDREFLLDFQF (622-634) 
binding eIF4E. Mader et al. tested different fragments of eIF4GI and their interaction with 
mouse eIF4E (Mader et al. 1995).  A 49 aa region in eIF4G (aa 409-457) was 
demonstrated to be necessary and sufficient for binding to eIF4E. The binding motif was 
determined further to 12 aa that are highly conserved amongst yeast eIF4G homologues. 
Studies by Marcotrigiango showed that eIF4G binds the dorsal, convex surface of eIF4E, 
which is found distal to the cap binding pocket (Marcotrigiango et al. 1999) (figure 12).  
 
Figure 12: X-ray crystal structure of murine eIF4E bound to 7-methyl GDP and an eIF4GII 
peptide resulting in a ternary complex. Ribbon diagrams of eIF4E (blue) and the eIF4GII 
peptide (orange). The eIF4GII peptide interacts with the helices H1 and H2 of eIF4E. 7-methyl 
GDP as ball-stick-representation. The binding site of 7-methyl GDP lies 35 Å from the eIF4GII 
binding site. PDB ID code 1EJH (Marcotrigiango et al. 1999).  
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Several other proteins are known to bind this site as do the 4E binding proteins 
(4E-BPs) (figure 13). During the interaction of eIF4E with 4E-BPs, the recognition site for 
eIF4G is sterically blocked and the assembly of the translation machinery inhibited 
(Ptushkina et al. 1999).  
Numerous proteins binding to eIF4E were found to have the conserved eIF4E 
binding motif YXXXXLΦ (X standing for any residue and Φ for any hydrophobic residue) 
(Volpon et al. 2006). This motif becomes structured and adopts an L-shaped 
conformation (extended chain/α helix) upon interaction with eIF4E (Marcotrigiano et al. 
1999). Studies of 4E-BP1 revealed that it indeed is intrinsically unstructured without 
eIF4E. Further observations demonstrate the competition of eIF4G and 4E-BPs for the 
same surface on eIF4E.  
As already shown in figure 11, eIF4GII is cleaved by the picornaviral proteases 
Lbpro and 2Apro during infection and causes inhibition of host cell protein synthesis (see 
1.5.2.2). 
 
Figure 13: X-ray crystal structure of murine eIF4E bound to 7-methyl GDP and an4E-BP 
peptide resulting in a ternary complex. Ribbon diagrams of eIF4E (blue) and the 4E-BP 
peptide (yellow). The 4E-BP peptide interacts with similar sites of eIF4E as the eIF4GII peptide. 7-
methyl GDP as ball-stick-representation. The binding site of 7-methyl GDP lies 35 Å from the 
eIF4GII binding site. PDB ID code 1EJH (Marcotrigiango et al. 1999). 
The only structural data available of eIF4GII is the X-ray structure of the 
conserved middle part of eIF4GII, aa 754-1003 (Marcotrigiano et al. 2001). This domain 
is known to interact with eIF4A and picornaviral IRESs. The structure was determined at 
2.4 Å resolution, displaying a crescent-shaped protein composed of ten α-helices. The 
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helices are arranged as five antiparallel α helical pairs, called HEAT repeats (four 
proteins give rise to its name: Huntingtin, elongation factor 3, protein phosphatase 2A 
and yeast PI3 kinase TOR1). The repeats generate a double layer of α helices stabilized 
by salt bridges and Van der Waals interactions building a hydrophobic core (figure 14). 
 
Figure 14: Ribbon diagram of the conserved central region (aa 745-1003) of human eIF4GII. 
View along the cylindrical axes of the α helices. The concave surface is built by the a helices on 
the right and the convex surface by the b helices to the left.  PDB ID code 1HU3 (Marcotrigiano et 
al. 2001).  
 
1.6.1.2 Eukaryotic initiation factor 4E (eIF4E) 
Eukaryotic initiation factor 4E, as eIF4G, belongs to the eIF4F complex of 
translation initiation factors. Its function is to regulate mRNA translation and nuclear 
mRNA export by binding the 7-methyl-guanosine cap at the 5’ end of cellular mRNA 
(Haghighat et al. 1997). Besides these processes, eIF4E is involved in oncogenic 
transformation (Sonenberg et al. 1998). eIF4E is regulated by phosphorylation, which 
was shown to reduce its cap-binding ability (Scheper et al. 2002). Unphosphorylated 
eIF4E, on the other hand, stimulates translation in vitro (Svitkin et al. 1996). The 
theoretical molecular weight of eIF4E is about 25 kDa. However, when analyzed by 
SDS-PAGE it runs at around 37 kDa (accession number: P06730).  
eIF4E has been successfully cocrystallized with an eIF4GI peptide, different 
types of possible cap-structures (N7- alkylated cap, 7-methylGpppG, 7-methyl GTP, 7-
methyl GDP), and 4E-binding protein 1 (4E-BP1) (Brown et al. 2007, Niedzwiecka et al. 
2002, Tomoo et al. 2002, Marcotrigiano et al. 1997, Marcotrigiano et al. 1999). 
Structures of ternary complexes of eIF4E with either m7GpppA/4E-BP1 or with eIF4G 
peptide/7-methyl-GDP are available as well. Furthermore, Volpon and colleagues 
recently determined the cap-free structure of human eIF4E by NMR techniques (Volpon 
et al. 2006) (PDB ID 2GPQ). 
 28 
Several structures of eIF4E bound to a cap-structure helped to identify the 
molecular contacts between them (Marcotrigiano et al. 1997, Marcotrigiano et al. 1999, 
Matsuo et al. 1997, Tomoo et al. 2003,). Murine eIF4E in the cap bound form resembles 
a cupped hand and consists of an eight-stranded antiparallel β-sheet supported by three 
long α-helices (Niedzwiecka et al. 2002). The cap-binding site of eIF4E is formed by a 
cavity on the molecules concave surface. During the binding of the cap analog m7GTP, 
the guanosine part is sandwiched between two conserved tryptophans (Trp56 and 
Trp102) holding the guanosine in place throughout the interaction. Furthermore, a third 
conserved tryptophan (Trp166) forms hydrogen bonds and Van der Waals interactions 
with the N7-methyl group (Marcotrigiano et al. 1997). The additional delocalization of the 
positive charge of the methyl group further stabilizes the stacking interaction by 
interaction with Glu103 of eIF4E. Furthermore, Volpon et al. demonstrated that cap 
addition modulates the conformation of the dorsal surface of eIF4E (Volpon et al. 2006).  
  
 
Figure 15: NMR structure of yeast translation initiation factor eIF4E in complex with 
m7GDP and eIF4GI (residues 393-490). Yeast eIF4E is shown in green and eIf4GI in purple The 
m7GDP is represented as yellow sticks. The light pink helix displays α4 of eIF4GI containing the 
conserved eIF4E binding motif YXXXLΦ. Residues 33-38 of eIF4E enclosed by eIF4GI are 
presented in blue (Gross et al. 2003). Created with PyMOL (Delano, 2002) using the PDB ID code 
1RF8.  
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Gross et al. solved the structure of the ternary complex between yeast eIF4E, 
eIF4G (residues 393-490) and m7GDP using multidimensional NMR (Gross et al. 2003) 
shown in figure 15. eIF4G was shown to adopt a ring-shaped structure of five helical 
regions (α1-α5) upon binding eIF4E. The consensus sequence YXXXLΦ is located in α4, 
which forms together with α1, α2, and α5 a hydrophobic cavity enclosing the N-terminal 
residues 33-38 of eIF4E. Furthermore, this sequence was demonstrated to be sufficient 
for binding of eIF4E to eIF4G (Mader et al. 1995). Residues 23-32 of eIF4E emerge from 
the cavity and fold into a turn/helix/extended chain structure. The contacts of yeast 
eIF4E/eIF4G are found at the convex surface of eIF4E as observed for the murine 
eIF4E/eIF4GII peptide complex (Marcotrigiano et al. 1999). Several residues of all five 
helices of eIF4G interact with eIF4E. These residues are highly conserved or similar in 
mammals. Additionally, hydrophobic and charged interactions between α5 of eIF4G and 
β2 and α3 of eIF4E are present.  
 
1.6.2 Cap-independent translation and host-cell shutoff 
Viruses are dependent on host cells for their replication and have evolved specific 
strategies to survive. Picornaviruses, except cardioviruses, developed a mechanism 
called host cell shutoff, which inhibits host cell protein synthesis and allows the virus to 
take over the host cell (Bedard et al. 2004).  
In contrast to eukaryotic mRNAs, viral mRNAs lack a 5’ cap structure recognized 
by the cap binding protein eIF4E. The recognition of the cap structure is important for the 
process of protein synthesis initiation. Upon viral infection, the cap-dependent translation 
(see 1.6.1) is prevented due to the cleavage of eIF4G by picornaviral proteases Lbpro and 
2Apro. The disruption of the eIF4G scaffolding function separates the eIF4E binding 
domain from the C-terminal domain which interacts with eIF3 that recruits the 40S 
ribosomal subunit. The cleavage of eIF4G by picornaviral proteases to block host cell 
translation was first observed in PV infected HeLa cells (Etchison et al. 1982).  
 
Figure 16: Translation initiation factors involved in cap-independent translation of 
picornaviruses. eIF4G is cleaved during viral infection by Lbpro or 2Apro. Hence,the complex can 
no longer recruit capped mRNA. However, the cleaved C-terminal part of eIF4G is sufficient to 
initiate viral translation via an IRES (Fields et al. 2007).  
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2 Aim of the work 
The reason for exploring Lbpro is to further understand the specificity and the 
reactions to design a possible inhibitor. Kleina et al. 1992 demonstrated that the 
inhibition of Lbpro activity in cells causes a 1000-fold reduction in virus yield. Thus, if the 
self-processing reaction is prevented, Lbpro is thought to remain connected to VP4. 
Accordingly, the assembly of viable viral particles might not be feasible anymore. 
Previous experiments showed that this is true for 2Apro of poliovirus (Crowder et al. 
2005). Therefore, the design of a functional inhibitor of Lbpro requires not only the X-ray 
crystal structure, but also knowledge about its interaction with the substrates.  
The aim of this work was to closer investigate the specificity of the Leu143 residue 
of FMDV Lbpro. This residue was formerly shown to be involved in the formation of the 
hydrophobic S2 pocket by binding Leu200 (Kuehnle et al. 2004). Furthermore, Lbpro as a 
cysteine protease gains its specificity mainly at the S2 position, only accepting leucine, 
valine and, to a certain extent isoleucine, (Santos et al. 2009). This specificity was 
attributed to Leu143 as it is pivotal for the discrimination of all other residues especially 
phenylalanine. The double mutant Leu200PheLeu143Ala showed that in this case Phe is 
accepted and even processed to wild-type levels. Therefore, Leu143 is essential for the 
conservation of the Lbpro specificity and one reason for the restricted number of 
substrates.  
 How does an active Lbpro L143A interact with its substrate eIF4GII? Based on the 
fact that only the two homologues of eIF4G are cleaved by wild-type Lbpro, we were 
interested in the change of specificity using Lbpro L143A. We assumed that the related 
cleavage sequence present in eIF4GII and not recognized by Lbpro wt, might be cleaved 
by the mutant Lbpro. This sequence contains Phe at P2 and Asp at P3, which should be 
accepted by Lbpro L143A. This would further shed light on the interaction of the leader 
protease with its substrate.  
What are the cleavage differences between Lbpro wt and Lbpro L143A? As the 
mutation L143A in Lbpro should lower the specificity of the protease, further cleavage 
products might be expected as the pocket of S2 is able to accept other residues.  
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3 Materials and Methods 
3.1 Bacterial culture 
3.1.1 Bacterial strains 
3.1.1.1 E. coli BL21 (DE3) pLysS (F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS (CamR)) 
E. coli BL21 (DE3) pLysS (Novagen) was used to express pET11d eIF4GII, 
pET11d Stop Lbpro wt, pET11d Lbpro L143A and pproExHTA – meIF4E. This strain is 
widely used for protein expression, mostly in combination with pET expression vectors. It 
is deficient in Ion and ompT proteases. DE3 indicates that the strain contains a λ-DE3 
and therefore carries a copy of the T7 bacteriophage RNA polymerase gene I under 
control of a lac promoter. The expression is induced by adding IPTG (Isopropyl β-D-1-
thiogalactopyranoside) and the gene under control of the T7 promotor will be expressed. 
In addition, the pLysS plasmid includes the T7 lysozyme gene, which suppresses basal 
expression. BL21 (DE3) pLysS is mostly used to express cytotoxic proteins. The plasmid 
also contains a chloramphenicol resistance gene, 30 µg/ml chloramphenicol were 
therefore added to the medium.  
 
3.1.1.2 E. coli BL21(DE3)pLysE (F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysE (CamR)) 
For the expression of pET11d LbproL143A the bacterial strain for expression was 
changed to E. coli BL21 (DE3) pLysE. BL21 (DE3) pLysE is similar to BL21 (DE3) pLysS 
and carries also the T7 lysozyme gene, but produces higher amounts T7 lysozyme to 
further reduce the basal level of expression.  
 
3.1.1.3 E. coli Top 10F’ 
To modify or amplify plasmids, the E. coli Top 10F’ strain (F-mcrA Δ(mrr-
hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1araD139 Δ(ara-leu)7697 galU galK rpsL 
endA1 nupG) from Invitrogen was used. 
 
3.1.1.4 Media and Solutions 
Luria Bertani (LB) medium (Roth) consists of 10 g/l tryptone, 5 g/l yeast extract 
and 10 g/l NaCl, pH 7.0 ± 0.2. Before using the medium it was autoclaved. This medium 
was used to grow bacteria for DNA amplification or recombinant protein expression. For 
the latter additional antibiotics were added before use (ampicillin: 100 µg/ml, 
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chloramphenicol: 30 µg/ml). LB-medium was used for protein expression of Lbpro wt, Lbpro 
L143A and eIF4GII.  
Terrific Broth (TB) medium contains 12 g tryptone, 24 g yeast extract and 4 ml 
glycerol per liter of culture. Before using the sterile TB-medium, 100 ml of a solution 
containing 0.17 M KH2PO4 and 0.72 M K2HPO4 were added as well as ampicillin (100 
µg/ml) and chloramphenicol (30 µg/ml). This medium was used to express eIF4E.  
 
3.1.1.5 Preparation of competent cells 
All three E. coli strains were made competent using a slightly modified protocol 
from D. Hanahan et al. “DNA Cloning Techniques”. 3 ml of 2 x TY were inoculated with 
cells directly from the -80°C freezer and incubated overnight at 37°C and 220 rpm. The 
overnight culture was used to incoluate 100 ml of 2 x TY, which was kept at 37°C at 220 
rpm until the OD600 reached about 0.5. This culture was divided into two 50 ml falcons 
and incubated 15 min on ice. After harvesting the cells at 2500 rpm, 15 min at 4°C, the 
supernatant was discarded and the pellet resuspended in 33 ml of RF1. This was then 
again incubated for 15 min on ice, centrifuged at 2500 rpm for 15 min at 4°C. The pellet 
was resuspended in 8 ml of RF2 and 200 µl aliquots were snap frozen.  
2 x TY:  16 g tryptone, 10 g yeast extract, 5 g NaCl, ad 1 L dH2O 
RF1:   100 mM KCl, 50 mM MnCl2 ·4 H2O, 30 mM CH3CO2K,  
10 mM CaCl2 · 2 H2O, 15 % (w/v) glycerol, adjust to pH 5.8 
RF2: 10 mM MOPS, 10 mM KCl, 75 mM CaCl2 · 2 H2O, 15 % (w/v) 
glycerol, adjust to pH 6.8 
 
3.1.1.6 Transformation of competent cells 
All E. coli strains were used for transformation. Per transformation 200 µl of 
competent cells were thawed on ice for 15 min. Depending on the sample a certain 
amount (e.g. 10µl for ligations, 1 µl for midi preps) was added to the cells and kept for 
another 15 min on ice. Samples were heat shocked at 42 °C for 45 seconds, 400 µl of 
preheated LB medium were added and then incubated at 37°C for at least 30 min. 
Between 150 and 200 µl were plated on LB- Amp Agar-Agar plates in the case of E. coli 
Top 10F’ cells and on Lb-Amp-Cam Agar-Agar plates in the case of E. coli BL21 (DE3) 
pLysS and E. coli BL21 (DE3) pLysE. Plates were incubated overnight at 37°C to allow 
colonies to grow.  
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LB-Amp Agar Agar plates: Add 1.5 % Agar-Agar to LB-Medium. Autoclave at 
120 °C for 20 minutes. Let cool down, add ampicillin 
(100 mg/L) and pour plates. 
 
3.2 DNA methods 
3.2.1 Plasmids for protein expression 
For the expression of recombinant proteins in either E. coli (DE3) pLysS or E. coli 
(DE3) pLysE, the vectors pproExHT a (Invitrogen) and pET11d (Novagen) were used. 
pproExHT a is 4779 bp in size and encodes sequences for T7 driven protein expression 
as well as the lacI gene. The vector carries additionally an ampicillin resistance selection 
marker. pET11d is 6165 bp in size and encodes the same regions as  pproExHT a. The 
induction of protein expression is possible by the addition of IPTG. 
 
3.2.2 Preparation of plasmid DNA from bacteria 
3.2.2.1 DNA mini prep 
Mini preps are small scale plasmid preparations of transformed E. coli cells to 
isolate and purify plasmid DNA (Birnboim and Doly 1979). These DNA preparations were 
used to screen for positive mutants.  
 4 ml of an LB-Amp culture were inoculated with a colony picked from a LB-Amp 
plate and. The samples were incubated at 37°C in a bacterial shaker overnight. The next 
day, cells were harvested in 1.5 ml tubes for two minutes at 6.000 rpm. After discarding 
the supernatant the spinning and discarding was repeated with the rest of the overnight 
culture. The pellet was resuspended in 100 µl of Solution I and then mixed gently with 
Solution II. 150 µl of Solution III were added and mixed again before centrifugation of the 
sample at 4°C for 10 minutes at 14.000 rpm. The supernatant was transferred into a new 
tube. For precipitation 1 ml of ice cold, 96 % ethanol was added and the tube inverted. 
After spinning down at 14.000 rpm for 5 min at 4°C, the pellet was taken up in 200 µl TE-
Buffer and 200 µl of 5 M LiCl were added. The centrifugation was repeated before the 
supernatant was transferred into a new tube and the DNA precipitated with 1 ml of ice 
cold 96 % ethanol. The pellet received after centrifugation was dried on air for about 1 
hour and the DNA taken up in 50 µl MILI-Q water. Isolated and purified DNA was stored 
at - 20 °C. 
 
 
 36 
Solution I:  50 mM Tris/HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNaseA 
Solution II:  20 mM NaOH, 1 % SDS 
Solution III:  2.8 M Potassiumacetate pH 5.1 
TE-Buffer:  10 mM Tris/HCl pH 8.0, 1mM EDTA 
 
3.2.2.2 DNA midi prep 
Midi preparations are middle scale DNA preparations to produce larger amounts 
of clean DNA.  The “Plasmid DNA Purification Kit” (Macherey-Nagel) was used to isolate 
DNA following the instructions of the company. The so purified plasmid DNA was taken 
up in 200 µl MILI-Q water and stored at - 20 °C.  Those DNA preparations were used for 
sequencing and recombinant protein expression.   
 
3.2.3 DNA quantification 
DNA concentrations were quantified using the Nanodrop spectrophotometer ND-
1000 from Peglab, following the instructions of the manufacturer.  
 
3.2.4 Agarose gel electrophoresis 
DNA gel electrophoresis was used to monitor the outcome of various reactions 
and procedures. The obtained DNA-fragments were separated on 1 % (w/v) agarose 
gels prepared with 0.5 x TAE buffer. 10 x loading buffer was added to the samples in the 
correct amount. The gels were run at 100-120 V using a power pack 300 from BioRad. 1 
µg of HindIII digested λ-DNA was used as size marker. The DNA-fragments were 
visualized by a UV-transilluminator after staining with ethidiumbromide for 20-30 min.  
0.5x TAE buffer:  20 mM Tris base, 5 mM sodiumacetate, 1 mM EDTA 
pH 8.2 
10 x Loading Buffer:    1 mM EDTA, 0.1 % Orange G, 10 % Ficoll in  
0.5 x TAE 
Ethidiumbromide solution:   10-4 % ethidiumbromide in 0.5 x TAE 
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3.2.5 Restriction digestion of DNA 
Preparative digestions of DNA were performed in a total volume of 20 µl. 
Restriction endonucleases and 10 x reaction buffers from New England BioLabs were 
used.  
Reaction:  x         µl  DNA 
 2       µl NEB buffer (1-4) 
 0.3-1   µl   enzyme 
 y         µl  dH2O 
The temperature and time of incubation was adapted to the enzymes chosen.  
 
3.2.6 DNA dephosphorylation 
To prevent religation of restricted plasmids the 5’-end of the DNA was 
dephosphorylated using calf-intestine alkaline phosphatase (CIP). After purification of the 
restricted vector using Wizard® SV Gel and PCR Clean-Up System (Promega) and 
elution in 44 µl of dH2O, 5 µl of NEB buffer 3 (New England BioLabs) and 1 µl of CIP 
(New England BioLabs, 10u/µl) were added. The reaction was incubated for 60 min at 
37°C. After dephosphorylation, the vector was again cleaned.  
 
3.2.7 Extraction of DNA from agarose gel 
To separate a certain DNA band from others a preparative 1 % (w/v) agarose gel 
was performed (80 ml of 0.5 x TAE and 0.80 g agarose). After staining with 
ethidiumbromide and visualizing the DNA bands by UV light the desired band was cut 
out and purified using the Wizard® SV Gel and PCR Clean-Up System.  
 
3.2.8 DNA ligation 
Before ligation, 1 µl of the dephosphorylated vector and 1 µl of the insert were 
loaded on a 1 % agarose gel to estimate their concentration. For ligation a ratio of 1:3 of 
vector to insert was used. The ligation itself was performed at room temperature for 3 
hours.  
   x     µl  vector 
   y     µl   insert 
   2     µl   10 x ligase buffer (Promega) 
   0.5  µl  T4 DNA ligase (Promega) 
   z     µl  dH2O 
 total of: 20   µl 
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3.2.9 DNA purification 
3.2.9.1 Wizard® SV Gel and PCR Clean-Up System (Promega) 
The Wizard® SV Gel and PCR Clean-Up System was used throughout the work 
to extract DNA from preparative agarose gels as well as for cleaning DNA (e.g. after 
PCR, dephosphorylation, restriction etc.).  
To extract DNA from a gel, the desired band was cut out and transferred into an 
eppendorf tube. An equal amount of membrane binding solution was added and heated 
at 60 °C until the gel slice was completely dissolved. To clean DNA, an equal volume of 
membrane binding solution was added. Further steps were done similar for both 
reactions.  
The SV minicolumn was inserted into the collection tube and either the dissolved 
gel mixture or the prepared PCR sample were transferred onto the minicolumn, 
incubated at room temperature for 1 min and centrifuged at 14000 rpm for 1 min. The 
flow-through was discarded and the column washed once with 700 µl and then with 500 
µl membrane wash solution. Centrifugation was done at 14.000 rpm for 1 and 5 min 
respectively. The collection tube was sucked dry with a vacuum pump and the 
minicolumn was reinserted and centrifuged again for 5 min at 14.000 rpm. To elute the 
DNA sample, the minicolumn was transferred into an eppendorf tube and 30 – 50 µl of 
dH2O were added. After 1 min of incubation at room temperature, centrifugation was 
repeated at 14.000 rpm for 1 min. Cleaned DNA was stored at - 20 °C. 
 
3.2.10 DNA sequencing 
DNA sequencing was performed by LGC Genomics (http://www.agowa.de/). For 
sequencing of pET11d Lbpro L143A, the primers T7 promotor and T7 terminator provided 
by the sequencing service were used. Plasmids were sent in 10 µl aliquot of 100 ng/µl. 
 
3.3 Protein methods 
3.3.1 Protein Expression in LB and TB media 
The expression of recombinant protein was accomplished in E. coli BL21 (DE3) 
pLysS or E. coli BL21 (DE3) pLysE using. Bacteria were transformed with the vector 
containing the cDNA coding for the desired protein. Then 100 ml of LB-Amp-Cam (100 
µg/ml and 30 µg/ml respectively) medium were inoculated with a single colony carrying 
the desired construct and incubated overnight at 37°C on the shaker. The overnight 
culture was diluted up to 1 L of LB-Amp-Cam and grown at 32 °C. Once the optical 
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density (OD600) of 0.6 was reached, protein expression was induced by adding IPTG. 
Before induction 25 ml were taken into a separate flask to monitor the growth without 
IPTG (uninduced fraction). The induced and the uninduced culture were then kept for a 
certain time at a certain temperature depending on the protein. After expression, cells 
were harvested by centrifugation at 5000 rpm for 15 min at 4°C. The pellets of the 
induced and uninduced fraction were resuspended in suitable lysis buffer and both 
stored at - 80 °C. 
Luria Broth medium: 10 g/l tryptone, 5 g/l yeast extract and 10 g/l NaCl pH 7.0 ± 
0.2 
 
Teriffic Broth medium: 12 g/l tryptone, 24 g/l yeast extract, 4 ml/l glycerol autoclave 
and then add 0.17 M KH2PO4 and 0.72M K2HPO4 
 
3.3.2 Preparation of E. coli BL21 (DE3) pLysS and E. coli BL21 (DE3) pLysE cell 
extracts 
To disrupt the cells, the resuspended bacterial pellets were thawed on ice and 
sonicated with the homogenizer Sonoplus HD 200 from Bandelin in combination with the 
probe tip MS 73D. The induced fractions were sonicated three times 30 sec at a cycle of 
40% and finally one continuous cycle for 15 sec. For the uninduced fraction, sonication 
was performed three times 30 sec at a cycle of 20%.  The tubes were kept on ice.  
1 ml of the induced fraction was taken into a clean eppendorf tube; the remaining 
29 ml were centrifuged at 18.000 rpm for 30 min at 4°C. 100 µl of the 1 ml aliquot of the 
induced fraction and of the uninduced fraction were taken as “total” sample for a SDS 
PAGE. The remaining was centrifuged at 13.000 rpm for 30 min at 4°C to separate the 
soluble fraction (supernatant) from the insoluble one (pellet). Aliquots of the soluble, 
insoluble and total sample were then investigated on a SDS PAGE.  
 The supernatant of the induced fraction was used for further protein purification 
steps (see 3.3.4).  
 
3.3.3 Preparation of HeLa S10 extracts 
HeLa S10 cell extracts were used to test the activity of Lbpro wt and Lbpro L143A 
as described in 3.3.13. First 1 l of HeLa cells were grown in suspension culture and 
harvested in log phase at 1.200 rpm, 10 min at 4°C (Beckmann- J6-HC centrifuge). After 
discarding the medium, the cells were washed once with 50 ml ice cold 1 x PBS and 
twice with 25 ml ice cold 1 x PBS. Between each washing step, centrifugation at 1.000 
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rpm for 8 min at 4°C was performed (Heraeus Megafuge 1.0 R). The pellet was 
resuspended in 1.5 volumes of hypotonic lysis buffer and allowed to swell on ice for 10 
min. Subsequently, cells were homogenized with 250 to 300 strokes in a suitable 
Wheaton Dounce homogenizer and the disruption of cells controlled with trypan blue, 
which colors selectively dead cells. To remove cell debris and nuclei, the extract was 
transferred to a 30 ml glass centrifuge tube (Correx) and centrifuged for 5 min at 3000 
rpm at 4°C (Sorvall HB-4 rotor). At increased rpms (13.000 for 20 min) mitochondria was 
removed as well. After dialysis for 2 to 3 hours at 4°C against 1 l of dialysis buffer, the 
cell extract was centrifuged in glass tubes at 13.000 rpm for 10 min at 4°C. Prior to 
aliquoting and snap-freezing, the upper white layer needs to be removed. The samples 
were stored at - 80 °C. 
Hypotonic lysis buffer: 10 mM HEPES adjust pH 7.6 with KOH, 10 mM 
CH3CO2K, sterile filtered and stored at 4°C 
 add 2 mM DTT before use 
 
Dialysis buffer: 10 mM HEPES adjust pH 7.2 with KOH, 90 mM 
CH3CO2K, sterile filtered and stored at 4°C 
 add 1 mM DTT before use 
 
3.3.4 Protein purification  
3.3.4.1 Fractionated ammonium sulfate precipitation 
Ammonium sulfate precipitation is a method to purify the protein by changing its 
solubility. In the first step of the fractionated ammonium sulfate precipitation 30 % (v/v) of 
saturated ammonium sulfate were added to the soluble fraction. This was kept stirring at 
4°C overnight. After centrifugation at 18.000 rpm for 30 min at 4°C, saturated ammonium 
sulfate up to 60 % (v/v) were added to the supernatant and stirred 4 h at 4°C. The 
solution was centrifuged at 11.000 rpm for 30 min at 4°C, and the pellet resuspended in 
4 ml Buffer B (per 1 l of culture). 
Buffer B:  50 mM Tris/HCl pH 8.0, 1 M NaCl, 1 mM EDTA, 5 mM DTT, 5 % 
(w/v) glycerol 
 
3.3.4.2 Dialysis 
To remove the excess of salt, dialysis against buffer B was performed. Hence, 
the protein solution was transferred into a dialysis membrane made of cellulose (Snake 
SkinTM Pleated Dialysis Tubing from Thermo Scientific) with a cut-off of 7 kDa. The bags 
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were placed in 500 ml Buffer B. The Buffer was changed twice, after 1.5 hours and after 
3 hours. Finally, the sample was dialyzed against 800 ml of buffer B overnight. Dialysis 
was performed on 4°C.  
 
3.3.4.3 FPLC 
Subsequently, the protein was purified further on an ÄKTA Fast Protein Liquid 
Chromatography (FPLC) system from Amersham Biosiences. Depending on the protein 
either anion-exchange chromatography (MonoQ 10/100 GL) or affinity chromatography 
(HisTrap HP, 1ml) was performed in the first purification step. Further purification was 
obtained using size-exclusion chromatography (HiLoad 26/60 Superdex 75 pg). Columns 
used are from GE Healthcare.  
 
3.3.4.3.1 Anion exchange chromatography 
Ion exchange chromatography retains proteins based on their ionic interactions. 
Anion exchange chromatography especially retains negatively charged proteins, which 
bind to positively charged functional groups on the stationary phase of the column.  
MonoQ 10/100 GL was used for the purification of Lbpro wt, Lbpro L143A and the 
eIF4E. Prior to loading the sample, the pumps and the loop were washed with filtered 
dH2O (column on bypass). Then the column was washed with two column volumes (CV) 
of filtered dH2O and equilibrated with 2 CV of the loading buffer (Buffer A). The filtered 
sample was loaded via a 10 ml loop or a 50 ml superloop onto the column. Depending 
on the protein the gradient was chosen (table 1). UV light at 280 nm was used for 
detection of the eluted fractions. 2 ml fractions were collected automatically. After the run 
the column was washed with filtered dH2O, 20 % ethanol and stored at room 
temperature.  
 Lbpro wt Lbpro L143A eIF4E fragment 
Buffer A 50 mM Tris HCl 8, 50 mM NaCl, 1 mM EDTA, 5 mM DTT, 5 % (v/v) glycerol 
Buffer B 50 mM Tris HCl 8, 1 M NaCl, 1mM EDTA, 5 mM DTT, 5 % (v/v) glycerol 
gradient 
5 column volumes (CVs) of 100% Buffer A, 
2.5 CVs of 0-30 % Buffer B, 
15 CVs of 30-60 % Buffer B, 
2 CVs of 60-100 % Buffer B  
and 5 CVs of 100 % Buffer B 
2 CVs of 100% Buffer A, 
10 CVs of 0-30 % Buffer B, 
6 CVs of 30-60 % Buffer B, 
2.5 CVs of 60-100 % Buffer B  
and 1 CV 100 % Buffer B 
Table 1: Gradient and buffers used for MonoQ 10/100 GL.  
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3.3.4.3.2 Size-exclusion chromatography 
Proteins in solution can be separated according to their size via size-exclusion 
chromatography. Throughout this work a HiLoad 26/60 Superdex 75 pg column was 
used for purification. The different proteins were always separated over 1.2 CVs of Buffer 
A. UV light at 280 nm was used for detection of the eluted fractions. 2 ml fractions were 
collected automatically.  
 
3.3.4.3.3 Affinity chromatography 
3.3.4.3.3.1 HisTrap HP 
The purification of tagged proteins is based on the interactions between the tag 
and immobilized ligands on the column. eIF4GII is tagged with histidine. Histidines 
tagged proteins show a high affinity for Ni2+ ions and are therefore selectively bound to 
immobilized Ni2+ ions on a column. This property is used for separation.  
To purify eIF4GII a 1 ml HisTrap HP column was used. Before use the column 
was washed with dH2O. To charge the column with Ni2+ ions, 5 ml 500 mM NiCl2 were 
loaded onto the column. After equilibration with HisTrap Binding Buffer, the sample was 
loaded via a 10 ml loop. To separate eIF4GII either a one step gradient (8 CV of 0 %, 30 
CV of 0 – 100% and 10 CV of 100 % HisTrap elution buffer) or a two step gradient (2 CV 
of 0 %, 12 CV of 0 – 35 %, 8 CV of 35 – 100 % and 10 CV of 100 % HisTrap elution 
buffer) were used. UV light at 280 nm was used for detection of the eluted fractions. 
Fractions of 1ml were collected and stored at 4°C.  
HisTrap binding buffer: 50 mM Tris/HCl pH 8.0, 50 mM NaCl, 10 mM 
imidazole 
HisTrap elution buffer: 50 mM Tris/HCl pH 8.0, 50 mM NaCl, 500 mM 
imidazole 
 
3.3.4.3.3.2 Binding to 7-Methyl-GTP Sepharose 4B beads 
eIF4E samples were first purified with MonoQ 10/100 GL (see 3.3.5.1). Fractions 
containing eIF4E were pooled and concentrated before dialysis against eIF4E binding 
buffer at 4°C. The next day 500 µl of eIF4E were incubated overnight at 4°C with 1 ml of 
7-Methyl-GTP Sepharose 4B beads (GE Healthcare). The unbound fractions were 
washed off with 6 ml eIF4E binding buffer and the beads incubated 3 h at 4°C with 600 µl 
eIF4E elution buffer. eIF4E was eluted with 10 ml eIF4E elution buffer and the beads 
were washed with 4 ml of the same buffer. For regeneration, the beads were washed 
with 20 ml dH2O, 20 ml 0.2 % SDS, again 20 ml dH2O and 20 ml 0.02 % sodium azide 
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and stored at 4°C. All wash and elution fractions were collected in 2 ml and 1 ml 
respectively.  
eIF4E binding buffer: 20 mM MOPS pH 7.6, 0.25 mM DTT, 0.1 mM EDTA, 
50 mM NaF, 100 mM KCl 
 
eIF4E elution buffer: 20 mM MOPS pH 7.6, 0.25 mM, DTT, 0.1 mM 
EDTA, 50 mM NaF, 500 mM KCl 
 
3.3.5 Protein concentration 
Protein samples were concentrated using Centriprep Centrifugal Filter Devices 
(Millipore) following the instructions of the manufacturer. The centrifugations were 
performed at 3.000 rpm at 4°C on a Beckman J6-MI centrifuge. 
 
3.3.6 Protein quantification 
Besides controlling the concentration of proteins by SDS PAGE, the Nanodrop 
spectrophotometer ND-1000 from Peglab was used according to the instructions of the 
manufacturer. 
 
3.3.7 SDS PAGE (Sodiumdodecylsulfate Polyacrylamide Gel electrophoresis) 
(Laemmli, 1970) 
SDS PAGE was performed according to the protocol of Laemmli 1970. For the 
gel electrophoresis the mini-PROTEAN® 3 system from BioRad was used and assembled 
according to the instructions. The composition of the gel is shown in table 2. The 
components of the separation gel were mixed whereupon TEMED was added last. The 
mix was then poured and overlaid with isopropanol. After polymerization, the gel was 
rinsed with water, the stacking gel mixture poured on top of it and a comb placed in the 
gel. The gel was arranged in a tank after polymerization and the tank filled with Laemmli 
running buffer. A certain amount of protein fractions were mixed with either 2 x or 5 x 
Laemmli sample buffer and heated at 95 °C for 10 min. The obtained samples were 
loaded on the gel and protein separation was achieved at 100-150 V using an 
electrophoresis power supply from BioRad. 7 µl Prestained Precision Plus Protein 
standards from BioRad were used as size marker.  
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         Separation gel 
  17.5 % (ml)          6 % (ml) Stacking gel (ml) 
30 %  Polyacrylamide (PAA) 3.500                   1.200 0.333 
2.5 % Bisacrylamide (BAA) 0.209                   0.209 0.104 
4 x      Lower gel solution (LGS) 1.500                   1.500   - 
4 x      Upper gel solution (UGS) -                           - 0.500 
dH2O 0.758                   3.060 1.060 
10 %  Ammoniumperoxidsulfate (APS) 0.050                   0.050 0.020 
Tetramethylethylenediamine (TEMED) 0.005                   0.005 0.002 
Table 2: Composition of "Laemmli" separation gel and stacking gel. 
LGS:     1.5 M Tris base pH 8.8, 0.4% SDS 
UGS:     0.5 M Tris base pH 6.8, 0.4% SDS 
2 x Laemmli sample buffer: 20 % glycerol, 10 % β-mercaptoethanol, 6 % SDS, 
125 mM Tris, 0.01 % Bromphenol Blue pH 6.8  
5 x Laemmli sample buffer: 50% glycerol, 25 % β-Mercaptoethanol, 15 % SDS, 
0.31 M Tris, 5 mg Bromphenol Blue, pH 6.8 
Laemmli running buffer:  25 mM Tris base, 0.2 M Glycine, 0.1 % (w/v) SDS 
 
3.3.8 Coomassie Staining of Polyacrylamide Gels 
The polyacrylamide gels were stained by incubation with coomassie staining 
buffer for about 20-30 min. Destaining of the gels occurred in lukewarm water overnight 
at room temperature. After destaining, the gels were vacuum-dried on Whatman TM 
3MM paper for 1 hour at 80 °C using a Slab Gel Dryer SGD 4050 from Savant. 
Coommassie staining buffer: 0.4 % (w/v) BioRad Coomassie Brilliant Blue R250, 
45 % (v/v) methanol, 10 % (v/v) acetic acid 
 
3.3.9 Western Blot 
For western blot analysis the protein samples and the Prestained Precision 
Protein marker were first separated by SDS PAGE. The proteins were then transferred to 
a PVDF ImmobilonTM-P Transfer Membrane, which was activated with methanol before 
use. The western blot sandwich consisted of 2 sponges and 3 pieces of WhatmanTM 
3MM paper soaked with transfer buffer which enclose the SDS gel and the transfer 
membrane. This was then put into a TE 22 Mini Transfer Tank Unit from Hoefer scientific 
instruments. Prior to blotting the tank was filled with transfer buffer and blotting was 
performed at 4°C either overnight at 40 mA or at 200 mA for 3 h.  
To analyze samples containing eIF4GII (either purified or from HeLa cell extract) 
the following procedure was performed: 
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For the immunoblot the transfer membrane was incubated with 5 ml blocking 
buffer for 30 min in a falcon tube at room temperature rolling to block unspecific binding 
sites. Subsequent, the membrane was incubated with the primary antibody (table 3) for 1 
hour at room temperature. The membrane was washed two times 10 min with 1 x PBS 
(Phosphate buffered saline) and 5 ml of the secondary antibody in 1 x PBS were added 
for 1 h at room temperature. Before detection, the membrane was washed three times 
10 min with 1 x PBS. In the case of alkaline phosphatase (AP) conjugated secondary 
antibodies, the membrane was incubated with 5 ml of alkaline phosphatase buffer, 25 µl 
of freshly made 5 % NBT and 25 µl of 2.5 % BCIP. Once proteins were visible (1-15 
min), the reaction was stopped with dH2O.  
 For the detection of histidine tagged proteins, the membrane was incubated with 
5 ml blocking buffer for 30 min at 4°C. Thereafter, additional 5 ml blocking buffer 
containing 1 µl of His Probe (final dilution of 1:10.000) were added to the membrane and 
incubated 1 h at 4°C.  Before detection, the membrane was washed 3 times with 1 x 
PBST and 2 x with 1 x PBS. For horseradish peroxidase (HPR) conjugated antibodies, 
the Super Signal® West Pico chemiluminescent substrate kit from Pierce was used. 
Therefore, the membrane was incubated for a few minutes with 1 ml of each of the two 
solutions and then wrapped into clingfilm. The membrane was exposed to an 
autoradiography film (BioMax MS film from Kodak).  
Transfer buffer: 1 % (w/v) glycine, 20 % (v/v) methanol, 25 mM Tris base 
pH 8.8 
Blocking buffer:  0.2 % Tween 20, 0.2 % I-Block (Tropix) in PBS 
PBS(T): 1.4 mM KH2PO4, 2.7 mM KCl, 4.3 mM Na2HPO4, 137 mM 
NaCl, (0.1 % Tween 20) 
Alkaline phopshatase: 5 mM MgCl2, 100 mM NaCl, 100 mM Tris HCl pH 9.6 
5% NBT: 5 % (w/v) nitro blue tetrazolium chloride in 90 % 
dimethylformamide 
2.5 % BCIP: 2.5 % 5-bromo-4-chloro-3-indolyl phosphate in dH2O 
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Primary antibodies dilution 
rabbit anti eIF4GI (N-terminal, antiserum, gift from 
R.Rhoads, Shreveport, LA) 
1:8.000 
rabbit anti Leader protease (antiserum) 1: 2.000 
His Probe TM horseradish peroxidase conjugated 
(Pierce) 
1:10.000 
 
Secondary antibody dilution 
anti rabbit IgG alkaline phosphatase coupled (Sigma) 1:5.000 
Table 3: List of primary and secondary antibodies used in this work for immunodetection. 
 
3.3.10 Blue Native PAGE (BN PAGE) 
Blue native PAGE was used to analyze proteins in their native state. It was 
developed to separate mitochondrial membrane proteins and complexes of 10 kDa to 
10.000 kDa (Ilka Wittig et al. 2006, Schägger and von Jagow 1991). The BN PAGE uses 
Coomassie blue G250 dye which provides the negative charges for the surface of the 
protein for the electrophoretic separation. Native proteins and complexes migrate to the 
anode as blue bands and are separated according to their molecular weight and/or size 
as in SDS PAGE. 
The solution for the sample gel is mixed out of the two stock solutions of 5 % and 
18 % acrylamide depending on the percentage of choice. Usually a gradient gel is used, 
but in this work either 10 or 15 % sample gels and 5 % stacking gels were used. Vertical 
gels are casted in a cassette out of two glass plates separated by spacers. After 
polymerization of the sample gel, covered with a layer of dH2O, the stacking gel is casted 
and the well comb inserted. The electrophoresis apparatus is assembled in the cold 
room and the water cooling turned on. After the removal of the comb the blue cathode 
buffer is poured into the upper chamber. Prior to loading, the samples were 
supplemented with ¼ volume of sample buffer and kept on ice. Following the loading of 
the samples, the anode buffer was poured into the lower buffer chamber. As soon as the 
power supply is connected to the electrophoresis unit, the electrophoretic run is started 
at 100 V overnight. 
When the blue dye front reached the half of the gel, the blue cathode buffer is 
replaced with the colorless cathode buffer and the run continued with maximal 400 V. 
Once the blue cathode buffer front reached the bottom of the gel, the run is stopped. 
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Proteins can then be visualized by staining with Coomassie between 3 h-overnight. After 
destaining, the gel can be kept in the destaining solution at 4°C or dried. 
 
 sample gel 5 % 15 % 
AB mix 0.5 ml 18 ml 35 ml 
Gel Buffer 3 x 2 ml 60 ml 50 ml 
Glycerin (87 %) - - 24.4 ml 
dH2O  101.9 ml 20.05 ml 
10 % APS 50 µl   
TEMED 5 µl   
Table 4: Composition of 10 x stock solutions of 5 % and 18 % acrylamide. 
For 1 gel:   17.89 ml 5 %, 100 µl APS (10 %), 10 µl TEMED 
    14.945 ml 18 %, 50 µl APS (10%), 5 µl TEMED 
 
AB mix:   48 g acrylamide, 1.5 g bisacrylamide in 100 ml dH2O 
Cathode Buffer: 50 mM Tricine, 15 mM Bistris pH 7.0, 0.02 % Coomassie 
brilliant blue G250 
Cathode Buffer 2: 50 mM Tricine, 15 mM Bistris pH 7.0 
Anode Buffer:   50 mM Bistris, adjust pH 7.0 with HCl 
Gel Buffer (3x):  1.5 M 6-aminocaproic acid, 150 mM Bistris pH 7.0 
Sample Buffer: 500 mM aminocaproic acid, 5 % Coomassie brilliant blue 
G250 
Staining solution: 125 mg Coomassie brilliant blue G250, 200 ml ethanol, 35 
ml acetic acid, ad 500 ml dH2O 
Destaining solution:  20 % methanol, 7.5 % acetic acid  
 
3.3.11 Activity assays with HeLa cell extracts 
Activity assays of HeLa cell extracts were performed with either Lbpro wt or Lbpro 
L143A. HeLa cell extracts contain eIF4GII, which is cleaved by all picornaviral proteases.  
8 – 10 µl of Hela cell extracts were incubated with different amounts of Lbpro wt or 
Lbpro L143A for 60 min at 30°C. The reaction was stopped with 5 x sample buffer, heated 
at 95 °C for 10 min and loaded on a 6 % SDS PAGE. After electrophoresis and western 
blot analysis, detection was performed as described in 3.3.10.  
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3.3.12 Processing assays with purified eIF4GII or eIF4GIIself 
To test the different cleavage properties of Lbpro wt and Lbpro L143A, the 
processing was observed on the purified eIF4GII fragment or eIF4GIIself. For this purpose 
1 µl of the substrate was incubated at 30°C for various times with different amounts of 
either Lbpro wt or Lbpro L143A. The reaction was stopped by adding 5x sample buffer, and 
the proteins separated on by 17.5% SDS PAGE. The gels were stained with 
Coommassie staining buffer for about 30 min and destained in lukewarm water 
overnight.  
In some processing assays eIF4E was preincubated with either eIF4GII or 
eIF4GIIself overnight at 4°C before the processing with the protease.  
 
3.3.13 MALDI-TOF Mass Spectrometry analysis 
MALDI-TOF MS (Matrix assisted laser desorption ionization – time of flight mass 
spectrometry) is used to identify proteins and peptides. The protein samples were first 
separated by SDS-PAGE and coomassie stained. After destaining, the desired protein 
band was cut out under lamina flow and the gel slice kept on ice in SDS running buffer. 
Before the measurements, the sample was enzymatically digested with trypsin. Trypsin 
is used very frequently, because each proteolytic fragment contains a basic arginine or 
lysine amino acid residue and therefore is suitable for positive ionization mass 
spectrometric analysis. The digested sample is analyzed without further clean up steps. 
The spectrum displays the molecular weight from the proteolytic fragments. This so 
called peptide map, is compared to theoretical mass values in databases (non-redundant 
database and a small internal database). If the protein exists in a database, the peptide 
map is sufficient to identify the protein. The measurements were performed at the Mass 
Spectrometry Facility of the Max F. Perutz Laboratories headed by Professor Gustav 
Ammerer. 
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4 Results 
4.1 Construction of Lbpro L143A 
The vector pET11d Lbpro L143A (figure 17) used to express Lbpro L143A was 
created by digesting the already available vectors pCITE Lbpro L143A L200F and pET11d 
Lbpro wt.  
 
Figure 17: Vector map of pET11d Lbpro L143A. The ampicillin resistance gene (Amp) and the 
lacI gene coding for the lac repressor protein are shown in blue and green, respectively. The gene 
of interest (Lbpro L143A) is displayed in magenta flanked by the T7 terminator and T7 promotor. 
The origin of replication (ori) and the T7 terminator and promoter are shown as red arrows.  
Both plasmids were cut with NcoI and BsiWI. The pCITE vector was cut in a way 
that only the L143A mutation remained. In contrast, the pET11d plasmid cut with the 
same enzymes, functions as vector (3.2.5). After the ligation of 2 µl vector and 2 µl insert 
for 2 hours at room temperature, 10 µl of the ligation were transformed into E. coli Top 
10F’ cells and plated on a LB-Amp plate (3.2.8). The plate was incubated overnight at 
37°C. The ligation was examined by digestion of minipreps with 0.3 µl NcoI and 0.3 µl 
BsiWI as a control before sequencing (3.2.10). Before using the plasmid for expression, 
midi preparations were done (3.2.2).  
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4.2 Expression and Purification 
4.2.1 Lbpro L143A and Lbpro wild-type 
Lbpro wt and Lbpro L143A, were expressed alike using E. coli BL21(DE3)pLysE 
cells. 2L of LB-Amp-Cam culture were used and the expression was induced with 0.3 
mM IPTG at an OD600 between 0.5 - 0.6. The protein was expressed at 16°C overnight 
(3.3.1). In both cases, the protease was not distinguishable from other proteins of similar 
size directly after expression and sonication. Figure 18 shows the 17.5% SDS gels of the 
soluble, insoluble and total fraction after sonication of Lbpro L143A (a) and Lbpro wt (b).  
 
Figure 18: Total (T), soluble (S) and insoluble (I) fractions of (a) Lbpro L143A and (b) Lbpro wt 
after sonication. Expressions of each protease were done in 2 L of LB-Amp-Cam culture using 
E. coli BL21(DE3)pLysE. 0.3 mM IPTG were used to induce each culture prior to overnight 
expression at 16°C. No IPTG was added to the uninduced fractions. 9 µl of the induced fractions 
(total of 60 ml) and 9 µl of the uninduced fractions (total of 1 ml) were loaded. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded). 
Subsequently, purification steps included the stepwise precipitation with saturated 
ammonium sulfate, purification by anion-exchange and size-exclusion chromatography 
(3.3.4). 
The chromatogram of the separation of Lbpro L143A by anion-exchange 
chromatography using the column MonoQ 10/100 GL is shown in figure 19a. A three 
step gradient of Buffer B was used for the separation. The 2 ml fractions A6-B4 were 
analyzed on a 17.5% SDS gel (figure 19b).  The fractions containing Lbpro L143A, A10-
A14 and A15-B4, were pooled and concentrated up to 1.5 and 1 ml, respectively. Both 
pools were used for subsequent size-exclusion chromatography. 
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Figure 19: Purification of Lbpro L143A by anion-exchange chromatography.  
(a) Chromatogram of Lbpro L143A purified by anion-exchange chromatography using a MonoQ 
10/100 GL column. 16 ml of the Lbpro L143A sample expressed in 2L of culture were loaded after 
stepwise precipitation. Fractions analyzed by SDS PAGE are indicated. (b) 17.5% SDS gel of 
fractions collected during anion-exchange chromatography. 9 µl of each fraction (total of 2 ml) and 
the loaded protein (Load- total of 16 ml) are present on the gel. Fractions A15-B4 were pooled 
and concentrated prior to separation by size-exclusion chromatography. The brown line 
represents the conductivity. The red arrow points at Lbpro L143A running at about 19 kDa. M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded). 
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Figure 20: Purification of Lbpro L143A by size-exclusion chromatography. (a) Chromatogram 
of Lbpro L143A purified by size-exclusion chromatography using a HiLoad 26/60 Superdex 75 pg. 
Lbpro L143A sample expressed in 2L of medium. Pooled fractions A15-B4 (1ml) of anion-
exchange chromatography were loaded. (b) Chromatogram of Lbpro L143A purified by size-
exclusion chromatography using a HiLoad 26/60 Superdex 75 pg. Lbpro L143A sample expressed 
in 2L of medium. Pooled fractions A10-A14 (1.5 ml) of anion-exchange chromatography were 
loaded. The brown curve represented in the chromatograms displays the conductivity.  (c) 17.5% 
SDS gel of fractions collected during size-exclusion chromatography shown in (a). 9 µl of each 
fraction (total of 2 ml) are present on the gel. Fractions F10-F13 and F14-G1 were pooled and 
each concentrated up to 1.5 ml. The red arrow points at Lbpro L143A running at about 19 kDa. M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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Lbpro wt was purified similarly. After stepwise precipitation with ammonium sulfate, 
the sample was loaded onto a MonoQ 10/100 GL column and 2 ml fractions collected 
using a three step gradient of Buffer B (3.3.4). The chromatogram is shown in Figure 
21a. Fractions A15-C6 were examined by 17.5% SDS gel (figure 21b) and  subsequently 
fractions B3-B8 were pooled and concentrated up to 1 ml for further size-exclusion 
chromatography, using a HiLoad 26/60 Superdex 75 pg column. 
 
 
Figure 21: Purification of Lbpro wt by anion-exchange chromatography. (a) Chromatogram of 
Lbpro wt purified by anion-exchange chromatography using a MonoQ 10/100 GL column. 20 ml of 
the Lbpro wt sample expressed in 2L of culture were loaded after stepwise precipitation. The brown 
line represents the conductivity. Fractions analyzed by SDS PAGE are indicated. (b) 17.5% SDS 
gel of fractions collected during anion-exchange chromatography. 9 µl of each fraction (total of 2 
ml) are present on the gel. Fractions B3-B8 were pooled and concentrated prior to separation by 
size-exclusion chromatography. The red arrow points at Lbpro wt running at about 19 kDa. M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
The chromatogram of Lbpro wt separated by size-exclusion chromatography is 
shown in figure 22a. The peak at fractions A1-A3 and fractions C3-C14 were analyzed 
by 17.5% SDS gel (figure 22b). Fractions containing Lbpro wt, C7-C14 were pooled and 
concentrated up to 600 µl before use in subsequent experiments. 
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Figure 22: Purification of Lbpro wt by size-exclusion chromatography. (a) Chromatogram of 
Lbpro wt purified by size-exclusion chromatography using a HiLoad 26/60 Superdex 75 pg. Lbpro wt 
sample of an expression in 2L of medium. Pooled fractions B3-B8 of anion exchange-
chromatography (1ml) were loaded. The brown line represents the conductivity. (b) 17.5% SDS 
gel of fractions A1-A3 and C3-C14 collected during size-exclusion chromatography and of the 
loaded sample (Load). 9 µl of each fraction (total of 2 ml) and 1 µl of the loaded sample are 
present on the gel. Fractions C7-C14 were pooled and concentrated up to 600 µl. The red arrow 
points at of Lbpro wt running at about 19 kDa. M indicates the Precision Plus Protein Standard All 
Blue from BioRad (7 µl loaded). 
 
Figure 23: Purified (a) Lbpro L143A and (b) Lbpro wt. 0.21 µg of Lbpro L143A and 5 µg of Lbpro wt 
are present on the gel. The indicated amount was loaded on a 17.5% SDS gel. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
Even though the expression and purification methods were equivalent the yield 
was quite different. Both proteases were expressed using 2L of culture. However, the 
concentration of Lbpro wt was 10 µg/µl and of Lbpro L143A only 0.1 µg/µl. Figure 23 shows 
the purified and concentrated samples used in the following processing assays. 
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4.2.2 eIF4GII and eIF4GIIself 
During my work, two different eIF4GII fragments were used, termed eIF4GII and 
eIF4GIIself (figure 24). Both comprise amino acids 552-745 of human eIF4GII (accession 
number: AF012072) and are theoretically 22 kDa in size, but were observed at 25 kDa 
on 17.5% SDS gels. For affinity purification and detection by western blot analysis, six 
histidine residues were added to the C-terminus of both substrates. Both fragments 
contain the eIF4E binding sequence (green in figure 24) and the related sequence not 
recognized by Lbpro wt (underlined in figure 24). eIF4GII contains the natural cleavage 
sequence recognized by Lbpro wt (LLNVG↓SRRSQ), whereas in eIF4GIIself (cloning 
performed by Katharina Ruzicska), the natural cleavage site is replaced by the Lbpro self-
processing sequence (QRKLK↓GAGQS). Both fragments were used in processing 
assays with either Lbpro wt or Lbpro L143A. 
 
Figure 24: Amino acid sequences of the human eIF4GII fragment and eIF4GIIself. (a) eIF4GII 
fragment (aa 552-745) containing the wt cleavage sequence LLNVG↓SRRSQ recognized by Lbpro 
wt. (b) eIF4GIIself fragment (aa 552-745). The natural cleavage site is replaced by the Lbpro self-
processing sequence QRKLK↓GAGQS. The eIF4E binding sequence is shown in green (Gradi et 
al. 2004) and the related sequence not recognized is underlined (Kuehnel et al. 2004).  Accession 
number of full-length human eIF4GII: AF012072.  
 
The expression of the eIF4GII fragment was performed in LB Amp/Cam medium 
using E. coli BL21(DE3)pLysS cells (3.3.1). After induction with 0.1 mM IPTG at an 
OD600 between 0.5 - 0.6, protein expression was continued for 5 h at 30°C. The 25 kDa 
eIF4GII fragment could be observed directly after sonication (figure 25). Most of it is 
found in the soluble fraction.  
eIF4GII is tagged with six histidine residues. Therefore, affinity chromatography 
was performed using a 1 ml HisTrap HP column (GE Healthcare) (3.3.4). The expressed 
eIF4GII (40 ml) from 4 liters of culture was loaded and separated using a one step 
gradient of HisTrap elution buffer. The chromatogram is shown in figure 26a (1st 
run/chromatography). The fractions A9-B6 were analyzed on the 17.5% SDS gels 
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presented in figure 26b. Fractions containing eIF4GII, A9-B6 (each 1 ml), were pooled 
and concentrated up to 500 µl for subsequent size-exclusion chromatography. 
 
 
Figure 25: Total (T), soluble (S) and insoluble (I) fractions of the eIF4GII-fragment. 1 µl of the 
induced fractions (total of 40 ml) from expression in 4 L of culture was loaded on the 17.5% SDS 
gel and 9 µl of the uninduced fractions. The red arrow indicates the eIF4GII fragment running at 
about 25 kDa.  M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl 
loaded).  
 
Figure 26: Purification of eIF4GII by affinity chromatography using a 1ml HisTrap HP 
column (1st run/chromatography). (a) Chromatogram of eIF4GII purified by affinity 
chromatography using a 1 ml HisTrap HP column. 40 ml of the eIF4GII sample expressed in 4 L 
of culture were loaded. The brown line represents the conductivity. Fractions analyzed by SDS 
PAGE are indicated. (b) 17.5% SDS gels of fractions collected during 1st run/chromatography. 2 
µl of each fraction (total of 1 ml) and 1 µl of the loaded sample (Load) are present on the gel. 
Fractions A9-B6 were pooled and concentrated up to 500 µl. The red arrow indicates the eIF4GII 
fragment running at about 25 kDa. M indicates the Precision Plus Protein Standard All Blue from 
BioRad (7 µl loaded).  
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The flow-through (39 ml) collected during the loading for the 1st 
run/chromatography (figure 26a) was loaded again on a 1 ml HisTrap HP column (2nd 
run/chromatography). The chromatogram of the second run is presented in figure 27a. 
Fractions A9-B6 were examined on the 17.5% SDS gel shown in figure 27b. Again, 
fractions A9-B6 were pooled and concentrated up to 500 µl for further size-exclusion 
chromatography. 
 
Figure 27: Purification of eIF4GII by affinity chromatography using a 1ml HisTrap HP 
column. (2nd run /chromatography) (a) Chromatogram of the 2nd run/chromatography loading 
the flow-through collected during the 1st run/chromatography (39 ml). Fractions analyzed by SDS 
PAGE are indicated. (b) 17.5% SDS gels of fractions collected during the 2nd run 
/chromatography. 2 µl of each 1 ml fraction are present on the gel. Fractions containing eIF4GII, 
A9-B6, were pooled and concentrated up to 500 µl for size-exclusion. The red arrow indicates the 
eIF4GII fragment running at about 25 kDa. M indicates the Precision Plus Protein Standard All 
Blue from BioRad (7 µl loaded).  
The concentrated fractions of both runs (1 ml) using 1 ml HisTrap HP column 
were pooled and purified by size-exclusion chromatography using a 26/60 HiLoad 
Superdex 75 pg column (3.3.4). The chromatogram of the separation by size-exclusion 
chromatography is shown in figure 28a. Fractions D8-E15, the loaded sample as well as 
the flow-through were examined on 17.5% SDS gels shown in figure 28b. Fractions D10-
E3 and E8-E15 were pooled and concentrated up to 1 ml. The fractions E4-E7 were not 
as pure as the other fractions and were therefore not used for further experiments.  
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Figure 28: Purification of eIF4GII by size-exclusion chromatography using a 26/60 HiLoad 
Superdex 75 pg column. (a) Chromatogram of eIF4GII purified by size-exclusion 
chromatography. 1 ml of the eIF4GII purified by affinity chromatography was loaded. The brown 
line represents the conductivity. (b) 17.5% SDS gels of fractions collected during size-exclusion. 9 
µl of each fraction (total of 2 ml) and 1 µl of the loaded sample (Load) and 1 µl of the flow-through 
(FT) are present on the gel. Fractions D10-E3 were pooled and concentrated up to 1 ml. The red 
arrow indicates the eIF4GII fragment running at about 25 kDa. M indicates the Precision Plus 
Protein Standard All Blue from BioRad (7 µl loaded).  
The second fragment eIF4GIIself contains the Lbpro self-processing site instead of 
the natural cleavage site. The purification procedure was similar. eIF4GIIself was 
expressed for 5 h at 30°C in 2L of LB Amp/Cam culture (3.3.1). The total, soluble and 
insoluble fractions obtained after sonication are shown in figure 39.  
 
Figure 39: Total (T), soluble (S) and insoluble (I) fractions of the eIF4GIIself fragment. 1 µl of 
the induced fractions (total of 20 ml for eIF4GIIself-from expression in 2 L of culture) was loaded on 
the 17.5% SDS gel and 9 µl of the uninduced fractions. The red arrow indicates the eIF4GIIself 
fragment running at about 25 kDa.  M indicates the Precision Plus Protein Standard All Blue from 
BioRad (7 µl loaded).  
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Subsequently, affinity chromatography was performed as the eIF4GIIself fragment 
is as well histidine tagged (3.3.4). A one step gradient of HisTrap elution buffer was used 
for the separation. The 20 ml of the eIF4GIIself sample obtained after sonication were 
divided and only 10 ml put on a 1 ml HisTrap HP column at once, as large amounts of 
protein failed to bind in previous experiments. Therefore, two runs were needed. The 
chromatograms of the 1st and 2nd  run are shown in figure 30a and b, respectivley.  
 
Figure 30: Purification of eIF4GIIself by affinity chromatography using a 1ml HisTrap HP 
column.  (a) Chromatogram of the 1st run/chromatography loading 10 ml of the eIF4GIIself sample 
from an expression in 2 L of culture. (b) Chromatogram of the 2nd run/chromatography loading the 
second 10 ml of the 2 L eIF4GIIself expression. The brown line represents the conductivity. 
Fractions analyzed by SDS PAGE are indicated.  
Fractions A11-B4 (1ml each) of the 1st run/chromatography were analyzed by 
17.5% SDS gel (figure 31a). Fractions, A11-B4, of the 2nd run/chromatography were also 
examined by SDS PAGE shown in figure 31b. Fractions A15-B4 of both runs were 
pooled and concentrated up to 600 µl for subsequent size-exclusion chromatography. 
Fractions A11-A14 of both runs were pooled and concentrated as well (600 µl) and 
stored at -80 °C. 
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Figure 31: 17.5% SDS gels of fractions collected during eIF4GIIself purification using a 1ml 
HisTrap HP column. eIF4GIIself was expressed in 2 L of culture. (a) 9 µl of the 1ml fractions A11-
B4 of the 1st run are present on the gel. (b) 9 µl of the flow-through collected during the 1st run 
(FT1) and 2nd run (FT2), 9 µl of the sample loaded (Load2) for  the 2nd run and 9 µl of A11-B4 (total 
of 1 ml) of the 2nd run are present on the gel. Fractions A15-B4 of both runs were pooled and 
concentrated up to 600 µl. The red arrow indicates the eIF4GIIself fragment running at about 25 
kDa. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
 Following affinity chromatography, the pooled and concentrated eIF4GIIself 
sample was loaded on a 26/60 HiLoad Superdex 75 pg column. The pooled fractions 
A15-B4 of both runs were loaded (1.2 ml). The chromatogram is presented in figure 32a. 
The 2 ml fractions E10-E15 and the loaded sample were examined by SDS PAGE 
(figure 32b). Fractions containing eIF4GIIself, E10-E15, were pooled and concentrated up 
to 600 µl for further processing experiments.  
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Figure 32: Purification of eIF4GIIself by size-exclusion chromatography using a 26/60 
HiLoad Superdex 75 pg column. (a) Chromatogram of eIF4GIIself purified by size exclusion 
chromatography. 600 µl of eIF4GIIself purified by affinity chromatography was loaded. The brown 
line represents the conductivity. (b) 17.5% SDS gel of fractions collected during size-exclusion. 9 
µl of each fraction (total of 2 ml) and 1 µl of the loaded sample (Load) are present on the gel. 
Fractions E10-E15 were pooled and concentrated up to 600 µl. The red arrow indicates the 
eIF4GIIself fragment running at about 25 kDa. M indicates the Precision Plus Protein Standard All 
Blue from BioRad (7 µl loaded). 
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The purified proteins, eIF4GII and eIF4GIIself, were examined by SDS PAGE 
(figure 33).The concentration of the eIF4GII fragment was slightly higher (10 µg/µl) than 
the concentration of eIF4GIIself (2 µg/µl). 
 
Figure 33: Purified (a) eIF4GII and (b) eIF4GIIself. 10 µg of eIF4GII and 2 µg of eIF4GIIself are 
present on the gel. The indicated amount was loaded on a 17.5% SDS gel. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
 
4.2.3 eIF4E 
In contrast to the previous expressions, eIF4E was expressed in TB medium using 
E. coli BL21(DE3)pLysS cells (3.3.1). TB was used for expression due to its higher 
nutritional value which is needed to express satisfying amounts of eIF4E. 0.1 mM IPTG 
was used to induce the expression between an OD600 of 0.5-0.6 for 5 h at 16°C. Figure 
34 shows the total, soluble and insoluble fraction of eIF4E after sonication. 
 
Figure 34: Total (T), soluble (S) and insoluble (I) fractions of eIF4E. 1 µl of the induced 
fractions (total of 40 ml eIF4E from expression in 4 L of culture) was loaded on the 17.5% SDS 
gel and 9 µl of the uninduced fractions. eIF4E sample should be running at about 37 kDa.  M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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Even though, the eIF4E posses a histidine-tag, it has been demonstrated that 
purification by affinity chromatography is not successful. Instead, it is better to perform 
the separation by anion exchange chromatography with a MonoQ 10/100 GL column 
directly after sonication using a three step-gradient of imidazole (3.3.4). 40 ml of eIF4E 
(expression in 4L of medium) were loaded via a 50 ml super-loop onto the column. The 
chromatogram is shown in figure 35a. The flow-through collected during the 1st run was 
again loaded (figure 35b). Both chromatograms show that the separation by MonoQ 
10/100 GL is not optimal and gives rise to a multitude of peaks.  
 
Figure 35: Purification of eIF4E by anion-exchange chromatography using a MonoQ 10/100 
GL column. (a) Chromatogram of eIF4E purified by anion-exchange chromatography. 40 ml of 
the eIF4E expressed in 4L of culture were loaded. (1st run/chromatography). (b) The flow-through 
(40 ml) collected during the 1st run was loaded again (2nd run/chromatography). The brown line 
represents the conductivity. Fractions analyzed by SDS PAGE are indicated (c) 17.5% SDS gel of 
fractions collected during the 2nd run/ chromatography. 9 µl of each fraction (total of 2 ml) and 1 µl 
of the collected flow-through (FT) are present on the gel. Fractions B1-B9 were pooled and 
concentrated up to 500 µl prior to separation by affinity chromatography using 1 ml 7-Methyl-GTP 
Sepharose 4B beads. (d) The same fractions as on the SDS PAGE were analyzed by western 
blot. 9 µl of the 2 ml fractions and 1 µl of the flow-through (FT) were loaded. The red arrow points 
at eIF4E running at about 35 kDa. An anti-His-antibody (Pierce) was used for detection. M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
Thus, the first separation by anion-exchange chromatography yielded little eIF4E 
(data not shown) Therefore, only fractions of the 2nd run possibly containing eIF4E, B1-
B3 (2ml fractions), were analyzed by SDS PAGE and western blot (figure 35c and d). A 
correct identification of the fractions containing eIF4E was only obtained by western blot 
analysis (3.3.9).   
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eIF4E is known to bind cellular mRNAs by interacting with the m7 GTP cap 
structure. This specific interaction was utilized for the last purification step by affinity 
chromatography using 1 ml of 7-Methyl-GTP Sepharose 4B beads that specifically bind 
eIF4E (3.3.4). After dialysis against the eIF4E binding buffer, the beads were incubated 
at 4°C overnight with 500 µl of concentrated sample. After the unbound sample (U1-U4) 
was washed out with eIF4E binding buffer (2 ml fractions), the beads were incubated for 
3 h with 600 µl of eIF4E elution buffer. Bound eIF4E was eluted with 10 ml of eIF4E 
elution buffer and 1 ml fractions collected (E1-E13). Before regeneration, the beads were 
washed with 5 ml of eIF4E elution buffer and 2 ml fractions collected (W1-W3). The 
beads were regenerated as described in 3.3.6.4. All fractions collected during the 
washing (U1-U4 and W1-W3) and elution steps (E1-E13) were analyzed by SDS PAGE 
(figure 36). Fractions, E1-E13, containing pure eIF4E were pooled and concentrated up 
to 600 µl. The unbound fractions U1-U4 still contained high amounts of protein and were 
therefore also pooled, concentrated up to 500 µl and purified again using 7-Methyl-GTP 
Sepharose 4B beads (data not shown). 
 
 
Figure 36: 17.5% SDS gels of eIF4E purification by affinity chromatography using 7-Methyl-
GTP Sepharose 4B. 9 µl of the unbound fractions (U1-U4; total of 2 ml), 9 µl the eluted samples 
(E1-E13; total of 1 ml) and 9 µl of the wash fractions (W1-W3; total of 2 ml) were loaded. 
Fractions E1-E13 were pooled and concentrated up to 600 µl. U1-U4 were pooled and 
concentrated as well and incubated again with the beads. M indicates the Precision Plus Protein 
Standard All Blue from BioRad (7 µl loaded).  
Before using eIF4E together with eIF4GII, eIF4GIIself and the leader protease, 
eIF4E was dialyzed against Buffer A. Figure 37 shows the purified eIF4E (pooled 
fractions E1-E13 as shown in figure 36) with a concentration of 0.5 µg/µl.  
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Figure 37: Purified eIF4E. 0.5 µg of eIF4E are present on the gel. The indicated amount was 
loaded on a 17.5% SDS gel. M indicates the Precision Plus Protein Standard All Blue from 
BioRad (7 µl loaded).  
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4.3 In vitro activity test with HeLa cell extract 
To test whether the expressed and purified proteases are functional, an activity 
assay with HeLa cell extract was performed. HeLa cell extracts contain both isoforms of 
eIF4G which are cleaved by active leader proteases (Lloyd et al. 2006). Therefore, 
different amounts of protease (2µl) were incubated with 8 µl of cell extract at 30°C for 60 
min. Reactions were stopped by adding 5x sample buffer (3.3.11). The samples were 
separated by 6% SDS PAGE and analyzed by western blot using the alkaline 
phosphatase system for detection (3.3.9). Lbpro performs a single cleavage thus 
separating the N-terminal one-third of eIF4G from the C-terminal two-thirds. Even though 
eIF4G has a predicted molecular mass of about 156 kDa, both homologues migrate as a 
series of bands on SDS PAGE, the lowest at 220 kDa. The reason for this heterologous 
mobility is a complex translation initiation scheme involving five different AUG initiation 
codons and alternative splicing producing five isoforms of eIF4G varying at the N-
terminus (Lloyd et al. 2006).  
 
Figure 38: Western Blot of activity test with HeLa cell extract. (a) HeLa cell extract incubated 
with different amounts of Lbpro L143A and (b) of Lbpro wt. Detection with rabbit anti-eIF4GI 
antibody and anti rabbit IgG alkaline phosphatase coupled (Sigma). All of the acitivity-test (10 µl) 
was loaded on the 6% SDS gel. M indicates the Precision Plus Protein Standard All Blue from 
BioRad (7 µl loaded).  
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The blot in figure 38b shows a good correlation between the amount of Lbpro wt 
and the cleavage rate of eIF4G. In contrast, the cleavage with Lbpro L143A (figure 38a) is 
not as consistent with the amount of protease used. As this was the first assay 
performed with both proteases, the concentrations were not the same for Lbpro wt and 
Lbpro L143A. Before further assays were performed, the concentrations were controlled 
by SDS PAGE (data not shown). Nevertheless, both proteases are active and able to 
cleave eIF4G. As expected Lbpro wt cleaves more efficiently compared to Lbpro L143A. 
 
4.4 Processing assays 
To investigate the different cleavage properties of Lbpro wt and Lbpro L143A, a 
variety of processing assays was performed and analyzed on 17.5% SDS gels. All of 
them contain either eIF4GII or the eIF4GIIself as substrate. In some cases eIF4E was 
added in different amounts. As described in 1.6.1, eIF4E binds the cap structure of 
cellular mRNAs and a particular domain of eIF4GII. This interaction is thought to further 
promote the cleavage of eIF4GII by proteases, as some experiments suggest that 
eIF4GII becomes more structured upon binding to eIF4E (Ohlmann et al. 1997). The 
hypothesis is that due to the the unfolded-to-folded transition, the Lbpro cleavage site 
becomes exposed, thus being better accessible for Lbpro and enhancing the processing 
event. We tried to reproduce these assumptions using Lbpro wt and Lbpro L143A. 
Furthermore, these assays should shed more light on the specificity of Lbpro wt, as 
Leu143 was shown to be highly involved its maintenance (Mayer et al. 2008). The 
second substrate tested, eIF4GIIself, carries the self-processing site of Lbpro 
QRKLK↓GAGQS instead of its wild-type cleavage sequence LLNVG↓SRRSQ. We 
wanted to test whether this site is processed even though the chemical environment is 
different.  
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4.4.1 Processing of eIF4GII with Lbpro wt 
The first cleavage performed with purified eIF4GII was with 0-20 ng of Lbpro wt 
incubated for 60 min at 30°C (3.3.12). The leader protease cleaves the eIF4GII fragment 
into a smaller fragment of about 11 kDa (cpC) and a larger one running at about 18 kDa 
(cpN) (figure 39).  
 
Figure 39: Processing assay with eIF4GII and Lbpro. The amounts of protease indicated were 
incubated with 1 µg of eIF4GII for 60 min at 30°C. 1 µl of protease (in different amounts) was 
used together with 1 µl ( = 1 µg) of eIF4GII and filled up with Buffer A to 13 µl. 13 µl of the assays 
and 12 µl of the negative controls (ø = 1 µg of eIF4GII not incubated; o = 1 µg of eIF4GII 
incubated) were loaded on a 17.5% gel. cpN and cpC indicate the larger and smaller processing 
products of eIF4GII, respectively. M indicates the Precision Plus Protein Standard All Blue from 
BioRad (7 µl loaded).  
The smaller product contains the histidine tag after cleavage (see figure 24a). 50 
ng of Lbpro wt are sufficient for the cleavage of 50% eIF4GII after 60 min at 30°C. An 
additional band is observable in processing of eIF4GII with 200 ng of Lbpro wt. However, 
this is most likely the front of the gel as a similar band is visible in the lane of the marker. 
In subsequent experiments, a time course was performed to determine the point 
when 50% eIF4GII are processed by Lbpro wt (figure 40). The incubation of 50 ng Lbpro wt 
from 10-60min with eIF4GII shows no major differences regarding cleavage progress. 
Therefore, another time course from 2-10min was performed. In both cases, 50% of 
eIF4GII were cleaved with 50 ng Lbpro wt after 10 min at 30°C.  
 
Figure 40: Time course of the processing assay with 50 ng Lbpro wt and eIF4GII. 50 ng of 
Lbpro wt were incubated for the indicated time (min) with 1 µg eIF4GII at 30°C. 13 µl were loaded 
on a 17.5% gel (2 µl of protease (total of 50ng) and 1 µl (= 1 µg) of eIF4GII filled up to 13 µl with 
Buffer A). cpN and cpC indicate the larger and smaller processing products of eIF4GII, 
respectively. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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A recurring problem with both proteases was that after several assays the larger 
cleavage fragment (cpN) was no longer visible as shown in figure 41a. Different 
approaches to restore this cleavage product were tested, but still the cause remains 
unclear. Neither the use of a new aliquot of eIF4GII (kept at -80°C) nor a new aliquot of 
Lbpro wt were able to restore the larger cleavage product. Additionally, eIF4E was added 
to the processing assay, but the intensity of the larger cleavage product also did not rise 
(figure 41b). Moreover, we found out that the eIF4GII fragment precipitates during the 
assay (figure 41c) which might be associated with the problems concerning the larger 
cleavage product of eIF4GII.  
 
Figure 41: Processing assays of eIF4GII with 50 ng Lbpro wt. (a) 1 µg of eIF4GII incubated for 
indicated time (min) with 50 ng of Lbpro wt at 30°C. (b) Addition of 1 µg eIF4E to 1 µg eIF4GII prior 
incubation with 50 ng of Lbpro wt at 30°C for the indicated time (min). (c) 50 ng of Lbpro wt 
incubated with 1 µg eIF4GII for 10 min at 25°C. 50P demonstrates the precipitated eIF4GII 
remaining in the tube after the incubated aliquot was taken out. ø represents the negative control 
of eIF4GII not incubated and o for eIF4GII incubated for 10 min at 30°C or 25 °C respectively. 
eIF4GII and eIF4E are indicated, as is the smaller cleavage product (cpC). The impurities in 
purified and concentrated eIF4E are shown as well. The size of larger cleavage product is 
indicated by cpN. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl 
loaded).  
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 Due to these problems, the native state of the protease and the substrate were 
observed by blue native gel electrophoresis (BN PAGE) (3.3.10). This might shed more 
light on the reason of the hardly observable larger cleavage product as it is present in the 
native state. eIF4GII and the processing products should be visible on the BN PAGE if 
they are in their native and folded state.  
 However, the larger cleavage product reappeared in subsequent processing 
assays again. 
 
4.4.2 Processing of eIF4GII with Lbpro L143A 
The procedure for the processing with Lbpro L143A remains the same as with 
Lbpro wt (3.3.12), as the parameters were important to compare the cleavage ability of the 
two constructs. The precipitation of eIF4GII occurs also during the incubation with Lbpro 
L143A. For each amount of Lbpro L143A a new tube was used. After 10 min the entire 
sample was taken out, the reaction stopped with 5x sample buffer and separated by SDS 
PAGE (figure 42). Buffer A was added to the empty tube and analyzed by SDS PAGE 
(50P, 25P, 10P and 5P). About half of the amount of eIF4GII (0.5 µg) were observed to 
precipitate during the assay. Besides the precipitation, the aberrant processing products 
generated by cleavage with Lbpro L143A were also visible as additional bands around 
cpN.  
 
Figure 42: Processing assay with different amounts of Lbpro L143A and eIF4GII. The 
amounts indicated on top were incubated with 1 µg of eIF4GII for 10 min at 25 °C. For each 
amount a separate tube was taken and the precipitant (50P, 25P, etc.) remaining after taking all of 
the sample out analyzed on a 17.5% SDS gel. ø, o and oP indicate the negative controls not 
incubated, incubated and the precipitant left in the incubated tube, respectively. cpN and cpC 
indicate the larger and smaller processing products of eIF4GII, respectively. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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A time course with eIF4GII and 50 ng of Lbpro L143A was performed as well. The 
point of 50% eIF4GII cleavage was determined to be 50 ng of Lbpro L143A incubated for 
10 min at 30°C (figure 43). 
 
Figure 43: Time course of the processing assay with 50 ng Lbpro L143A and eIF4GII. 50 ng 
of Lbpro L143A were incubated for the indicated time (min) with 1 µg eIF4GII at 30°C. 13 µl were 
loaded on a 17.5% gel (2 µl of protease (total of 50ng) and 1 µl (= 1 µg) of eIF4GII filled up to 13 
µl with Buffer A). cpN and cpC indicate the larger and smaller processing products of eIF4GII, 
respectively. The red arrows point at the aberrant cleavage products generated only with Lbpro 
L143A not with Lbpro wt. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 
µl loaded).  
The processing of eIF4GII with Lbpro wt produces only two cleavage products, cpN 
and cpC (figure 39 and 40). In contrast, the mutant form Lbpro L143A gives rise to some 
additional cleavage products besides cpN and cpC (figure 43 and 44). Mayer et al. 
proposed that the specificity of the Lbpro L143A is lower than the one of the wild-type 
protease (Mayer et al. 2008). Therefore, Lbpro L143A is expected to recognize additional 
sites thus producing additional cleavage products. As these aberrant products could 
provide information about alternative sequences recognized by Lbpro L143A, two 
additional cleavage products were analyzed by mass spectrometry (3.3.13). 
 
Figure 44: Processing assay of eIF4GII with Lbpro L143A. The amounts indicated on top were 
incubated with 1 µg of eIF4GII for 60 min at 30°C and separated on a 17.5% SDS gel. ø and o 
represent the not incubated and incubated negative control, respectively. cpN and cpC indicate the 
larger and smaller processing products of eIF4GII, respectively. The red arrows point at the 
aberrant cleavage products generated only with Lbpro L143A not with Lbpro wt. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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4.4.1 Mass spectrometry on eIF4GII cleavage products generated by Lbpro 
L143A 
Lbpro L143A generates more cleavage products on eIF4GII than Lbpro wt. Two of 
these additional processing products were chosen and analyzed using mass 
spectrometry (3.3.13). The processing assays were performed with 1µl of eIF4GII and 
either 100 ng or 50 ng of Lbpro wt or Lbpro L143A. The reaction was stopped with sample 
buffer after 40 or 50 min of incubation at 30°C and the samples were separated on a 
17.5% SDS gel. In contrast to former processing assays, more attention to the handling 
was given. Especially any contamination with dust particles, hair or skin should be 
prevented. Therefore, all solutions were filtered through 0.22 µm sterile membrane filters 
and the whole equipment properly washed with ethanol. Following the electrophoresis, 
the gel was stained with Coomassie and destained with a destaining solution (30% 
methanol, 8% acetic acid) in a closed dish. The gel bands highlighted in figure 45 were 
cut out under the lamina flow and covered with SDS running buffer. The two cleavage 
products were separately analyzed by mass spectrometry and the data compared to the 
nr-database and to a small internal database (containing often occurring contaminations 
as creatine, common proteins but also proteases used during the experiment). The 
results for both samples are shown in figure 46 and 47.  
 
Figure 45: Processing assay of Lbpro wt /Lbpro L143 A with eIF4GII for mass spectrometry. 
100 ng and 50 ng of both proteases were incubated for 40 and 50 min at 30°C before loading on 
a 17.5% SDS gel. The samples for mass spectrometry analysis were cut out. Sample A and B are 
indicated with arrows. cpN and cpC indicate the larger and smaller processing products of eIF4GII, 
respectively. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
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The following parameters were used for the measurements of both samples: 
 
Enzyme: Trypsin 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Mass values: Monoisotopic 
Protein Mass: Unrestricted 
Peptide Mass Tolerance: ± 5 ppm 
Fragment Mass Tolerance: ± 0.8 Da 
Max Missed Cleavages: 2 
Instrument type: LTQ Orbitrap Velos 
 
     1 HPERDPSDLK KVKAVEENGE EAEPVRNGAE SVSEGEGIEA NSGSTDSSGD  
    51 GVTFPFKPES WKPTDTEGKK QYDREFLLDF QFMPACIQKP EGLPPISDVV  
   101 LDKINQPKLP MRTLDPRILP RGPDFTPAFA DFGRQTPGGR GVPLLNVGSR  
   151 RSQPGQRREP RKIITVSVKE DVHLKKAENA WKPSQKRDSQ ADDHHHHHH  
 
Figure 46: Matched peptides for sample A. In red the matching peptides are shown, resulting 
from the comparisons of sample A with the two databases.  
 
     1 HPERDPSDLK KVKAVEENGE EAEPVRNGAE SVSEGEGIEA NSGSTDSSGD 
    51 GVTFPFKPES WKPTDTEGKK QYDREFLLDF QFMPACIQKP EGLPPISDVV 
   101 LDKINQPKLP MRTLDPRILP RGPDFTPAFA DFGRQTPGGR GVPLLNVGSR  
   151 RSQPGQRREP RKIITVSVKE DVHLKKAENA WKPSQKRDSQ ADDHHHHHH  
 
Figure 47: Matched peptides for sample B. In red the matching peptides are highlighted, 
resulting from the comparisons of sample B with the two databases.  
 Several peptides corresponding to the eIF4GII fragment were found and matched 
to the sequence. However, contaminations of other proteins cannot be excluded. An 
additional cleavage site could not be determined by mass spectrometry analysis on 
sample A and B. The related sequence AFADFGXRQTPGG (X stands for the potential 
site of cleavage) in eIF4GII was expected to be recognized by Lbpro L143A. This was not 
confirmed by an explicit sequence received by mass spectrometry. Furthermore, no 
other potential cleavage sites were observed.  
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4.4.2 Processing of eIF4GIIself with Lbpro wt 
In addition to the eIF4GII fragment, a second fragment termed eIF4GIIself was 
used for processing assays. This fragment contains the self-processing site of the leader 
protease QRKLK↓GAGQS instead of its wild-type cleavage sequence LLNVG↓SRRSQ. 
The chemical environment of eIF4GII is totally different than the one present during the 
self-processing reaction.  
 
Figure 48: Processing assay of eIF4GIIself with different amounts of Lbpro wt. 1 µg of 
eIF4GIIself was incubated with different amounts of Lbpro wt for 10 min at 30°C. ø and o represent 
the negative controls which are either not incubated or incubated for 10 min, respectively. cpN and 
cpC indicate the larger and smaller processing products of eIF4GIIself, respectively. M indicates the 
Precision Plus Protein Standard All Blue from BioRad (7 µl loaded).  
 
However, the sequence was recognized and cleaved by Lbpro wt. Figure 48 
shows that 50% of eIF4GIIself were already cleaved with 15 ng of Lbpro wt after 10 min at 
30°C. In contrast, to obtain 50% of cleavage with eIF4GII fragment containing the wild-
type cleavage site, 50 ng of the wild-type protease were needed. 
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4.4.3 Processing of eIF4GIIself with Lbpro L143A 
The cleavage properties of Lbpro L143A were also tested with eIF4GIIself. Figure 
49 reveals that 6.25 ng of Lbpro L143A are sufficient for processing 50% of eIF4GIIself. 
The amount of protease needed to cleave eIF4GIIself is also much lower than for eIF4GII 
for which 50 ng of Lbpro L143A are required.  
 
Figure 49: Processing assay of eIF4GIIself with different amounts of Lbpro L143A. 1 µg of 
eIF4GIIself was incubated with different amounts of Lbpro L143A for 10 min at 30°C. ø and o 
represent the negative controls which are either not incubated or incubated for 10 min, 
respectively. cpN and cpC indicate the larger and smaller processing products of eIF4GIIself, 
respectively. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded). 
 
4.4.4 Processing of eIF4GII with Lbpro wt or Lbpro L143A in presence of eIF4E 
During cap-dependent translation initiation, eIF4GII works as scaffolding protein 
co-ordinating the components of the translation initiation complex eIF4F. Once eIF4GII 
binds the cap-binding protein eIF4E, it is thought to undergo an unfolded-to-folded 
transition. Hence, the cleavage site for Lbpro on eIF4GII is thought to become more 
accessible to the protease, thus enhancing the processing event (Ohlmann et al. 1997, 
Gross et al. 2003). We wanted to reproduce these findings by incubating eIF4GII 
together with eIF4E overnight at 4°C to enable complex formation prior to cleavage 
(3.3.12). First, a 1:1 ratio of eIF4GII-eIF4E (1µg of each) was chosen and the complex 
was incubated with 50 ng of protease up to 60 min at 30°C. The incubation of the 
complex with 50 ng of Lbpro wt is shown in figure 50a. Figure 50b shows the processing 
assay of eIF4GII-eIF4E with Lbpro L143A. With both proteases, most changes occur 
within the first ten minutes of incubation as no major differences are observed when 
incubated longer. Furthermore, no significant improvement of cleavage can be observed 
when compared to the processing assays of Lbpro wt or Lbpro L143A with only eIF4GII 
(figure 40 and 43, respectively).  
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Figure 50: Time course of the processing assay of 1:1 ratio of eIF4GII:eIF4E with 50 ng (a) 
Lbpro wt or (b) Lbpro L143A. 50 ng of protease were incubated for the indicated time (min) with 
eIF4GII-eIF4E at 30°C. 13 µl were loaded on a 17.5% gel (2 µl of protease (50 ng) and 2 µl of the 
eIF4GII-eIF4E complex (1 µg each) filled up to 13 µl with Buffer A). cpN and cpC indicate the 
larger and smaller processing products of eIF4GII, respectively. Impurities of the eIF4E sample 
run between 100-40 kDa. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 
µl loaded).  
In addition, 1:1, 1:2 and 1:3 ratios of eIF4GII:eIF4E were examined (figure 51). 
No major differences were observed with higher ratios of eIF4GII:eIF4E. Before, the 
point of 50% eIF4GII processing was determined to 50 ng of Lbpro wt or Lbpro L143A after 
10 min incubation at 30°C. Therefore, the processing assay with the eIF4GII-eIF4E 
complex was performed at 10 min and 30°C. However, the 50% cleavage point is not as 
clearly as before and slightly more eIF4GII seems to be cleaved in presence of eIF4E 
after 10 min. Furthermore, two larger processing products cpN were obtained with Lbpro 
L143A; a very faint one of the same size as cpN (18 kDa) generated with Lbpro wt, the 
second is slightly smaller (16 kDa) than the cpN after cleavage with Lbpro wt. The one 
running at about 16 kDa is more prominent than the one at 18 kDa.  
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Figure 51: Processing assay with different ratios of eIF4GII:eIF4E and 50 ng Lbpro wt or 
Lbpro L143A. 50 ng of the protease were incubated with a 1:1, 1:2 or 1:3 ratio of eIF4GII:eIF4E for 
10 min at 30°C. o represents the incubated 1:1 ratio of eIF4GII:eIF4E. cpN and cpC indicate the 
larger and smaller processing products of eIF4GII, respectively. Impurities of the eIF4E sample 
run between 100-40 kDa. M indicates the Precision Plus Protein Standard All Blue from BioRad (7 
µl loaded).  
According to Slepenkov et al., the optimal ratio of eIF4GII:eIF4E is with equal or 
lower amounts of eIF4E (Slepenkov et al. 2008). Hence, 1:1, 1:0.5 and 1:0.25 ratios of 
eIF4GII:eIF4E were incubated prior to cleavage with either Lbpro wt or Lbpro L143A (figure 
52). The size difference of cpN obtained with Lbpro L143A is again visible when incubated 
with equal and lower amounts of eIF4E. Besides this, no major differences were 
observed when different ratios of eIF4E were used compared to the processing assays 
using only eIF4GII.  
 
Figure 52: Processing assay with different ratios of eIF4GII:eIF4E and 50 ng Lbpro wt or 
Lbpro L143A. 50 ng of the protease were incubated with a 1:1, 1:0.5 or 1:0.25 ratio of 
eIF4GII:eIF4E for 10 min at 30°C. ø and o represents the not incubated and incubated 1:1 ratio of 
eIF4GII:eIF4E. cpN and cpC indicate the larger and smaller processing products of eIF4GII, 
respectively. Impurities of the eIF4E sample run between 100-40 kDa. M indicates the Precision 
Plus Protein Standard All Blue from BioRad (7 µl loaded). 
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4.4.5 Processing of eIF4GIIself with Lbpro wt or Lbpro L143A in presence of eIF4E 
The assays described in 4.4.4 were performed similarly way the eIF4GIIself 
fragment. In contrast to eIF4GII, eIF4GIIself as substrate produced only cleavage products 
of the same size (18 kDa) with both proteases (figure 53). The ratio of eIF4GIIself 
remained unaltered, whereas the amount of eIF4E was changed. For the processing 
assays the amount of protease cleaving 50% of eIF4GIIself after 10 min at 30°C was 
chosen. These were 15 ng in case of Lbpro wt and 6.25 ng of Lbpro L143A. As with 
eIF4GII:eIF4E no significant differences were observed with the complex of 
eIF4GIIself:eIF4E. However, the size difference of cpN observed with Lbpro L143A cleaving 
eIF4GII in the binary complex was not detectable when eIF4GIIself was used as substrate 
with eIF4E.  
 
Figure 53: Processing assay with different ratios of eIF4GIIself:eIF4E and 15 ng Lbpro wt or 
6.25 ng Lbpro L143A. The protease was incubated with a 1:1, 1:2 or 1:3 ratio of eIF4GIIself:eIF4E 
for 10 min at 30°C. ø and o represents the not incubated and incubated 1:1 ratio of 
eIF4GIIself:eIF4E. cpN and cpC indicate the larger and smaller processing products of eIF4GIIself, 
respectively. Impurities of the eIF4E sample run between 100-40 kDa. M indicates the Precision 
Plus Protein Standard All Blue from BioRad (7 µl loaded).  
 
4.4.6 Processing of eIF4GII with Lbpro wt in presence of eIF4E, m7GTP 
As mentioned in 1.6.1, the cap binding protein eIF4E interacts with the 5’ cap 
structure of host cell mRNAs. The structure present at the 5’ end of the host mRNA is a 
7-methylguanosine linked to the mRNA via a triphosphate bridge. As eIF4E binds to this 
structure, the use of additional m7GTP in the processing assays might enhance the 
binding of eIF4GII to eIF4E as proposed by Haghighat et al. 1997. Hence, the ternary 
complex of cap, eIF4E and eIF4GII might be a better substrate for the protease. 100 µM 
m7GTP were added to eIF4G:eIF4E in the ratios 1:1, 1:2 and 1:3 (figure 54). The three 
components were incubated overnight at 4°C to enable the formation of the ternary 
complex. 50 ng of Lbpro wt were used for cleavage at 30°C for 30 min. This experiment 
was mainly done to restore the larger cleavage product, which became very faint after 
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some assays (figure 41). The idea was that the addition of eIF4E and m7GTP might 
restore the hardly visible larger cleavage product (cpN) running at about 18 kDa. 
Surprisingly, the smaller processing product running at about 11 kDa was detectable. 
Therefore, eIF4GII was processed by Lbpro wt even though no uncleaved eIF4GII is 
present on the SDS gel.  
 
Figure 54: Processing assay with different ratios of eIF4GII:eIF4E and 50 ng Lbpro wt. 50 ng 
of the protease were incubated for 10 min at 30°C with a 1:1, 1:2 or 1:3 ratio of eIF4GII:eIF4E 
without and with 100 µM m7GTP, respectivley. ø and o represents the not incubated and 
incubated 1:1 ratio of eIF4GII:eIF4E. cpN and cpC indicate the larger and smaller processing 
products of eIF4GII, respectively. Impurities of the eIF4E sample run between 100-40 kDa. M 
indicates the Precision Plus Protein Standard All Blue from BioRad (7 µl loaded). 
 
4.5 Observing the native state by blue native gel 
gelectrophoresis 
In order to investigate the origin of the problems with the larger cleavage product 
(cpN), obtained by cleavage of eIF4GII by the Lbpro wt, the native state of the proteins 
was observed by means of blue native gel electrophoresis (BN-PAGE). Not only the 
processing assays but also the binary complex eIF4G:eIF4E and the ternary complex 
eIF4G:eIF4E with 100 µM m7GTP were analyzed (3.3.10). This should shed light on the 
one hand on the native state of eIF4GII. On the other hand, we wanted to observe the 
interaction of the different components of the complex. For the processing assay, 50 ng 
of Lbpro wt were used to cleave eIF4GII at 30°C for 10-30 min. The cleavage reaction 
was stopped with 4 µl BN-sample buffer.  
At first a 10% BN-PAGE was performed, but the percentage was too low to see the 
smaller cleavage fragment. Figure 55 shows the 10% BN-PAGE displaying the 
processing assay of eIF4GII with 50 ng of Lbpro wt on the left and the binary (eIF4GII-
eIF4E) and ternary (eIF4GII-eIF4E-m7GTP) complex formation on the right.  
 80 
 
Figure 55: 10% BN-PAGE showing the processing assay and the complex formation. The 
processing assay of 50 ng Lbpro wt with 3 µg eIF4GII is displayed at the left side of the gel. 
Incubation at 30°C and various times (min). At the right side, the binary complex of eIF4GII-eIF4E 
and the ternary complex eIF4GII-eIF4E-m7GTP are loaded. ø and o represent the not incubated 
and incubated negative control of eIF4GII for the processing assay. ø on the right side indicates 
the not incubated 1:1 complex of eIF4GII-eIF4E. cpN indicates the larger processing product of 
eIF4GII. M indicates the Precision Plus Protein Standard All Blue from BioRad (12 µl loaded). 
Therefore, a 15 % BN-PAGE was prepared (data not shown). The gel again did not 
run long enough to observe the smaller cleavage products. Nevertheless, the larger 
cleavage products were visible on both BN-PAGEs. Therefore, we assumed that eIF4GII 
was still functional and hence in its native state. The formation of the binary or ternary 
complex was not confirmed explicitly by BN-PAGE. The eIF4GII fragment can be 
assigned to bands running at about 25 kDa. However, neither eIF4E nor the binary or 
ternary complex can be definitely identified on the BN-PAGE. To demonstrate the 
formation of the eIF4GII-eIF4E, complex various parameters for the BN-PAGE would 
need to be tested.  
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4.6 Complex formation of eIF4E with the eIF4GII fragment 
The eIF4GII fragment we were working with has a theoretical molecular weight of 
about 22 kDa containing the amino acids 552-745 of wild-type human eIF4GII. This 
fragment contains the conserved eIF4E binding motif YXXXXLΦ as well as the cleavage 
sites recognized by the Lbpro and HRV2 2Apro. Mader et al. have documented the binding 
of different eIF4GII fragments to eIF4E wild-type in vitro (Mader et al. 1995). This 
property was investigated to confirm the hypothesis that binding of eIF4E to eIF4GII 
enhances the cleavage by Lbpro. 
 Two different approaches were tested whether wild-type human eIF4E binds to 
the fragment of human eIF4GII. On the one hand, we tried to demonstrate the formation 
of the binary complex via size-exclusion chromatography using a HiLoad 16/60 
Superdex 75 pg column (3.3.4). On the other hand, the property of eIF4E binding the 5’ 
cap structure of mRNAs was exploited. Hence, 7-Methyl-GTP Sepharose 4B beads were 
used that are known to bind eIF4E. Thus, if eIF4GII binds to eIF4E both can be identified 
using 7-Methyl-GTP Sepharose 4B beads. 
 
4.6.1 HiLoad 16/60 Superdex 75 prep grade gel filtration column 
 First, we tried to determine the presence of the complex using a HiLoad 16/60 
Superdex 75 prep grade gel filtration column from GE Healthcare. To determine the 
approximate size of the proteins, the column was calibrated with a gel filtration low 
molecular weight calibration kit from GE Healthcare containing ribonuclease A (13.7 
kDa), carbonic anhydrase (29 kDa) and ovalbumin (43 kDa). To determine the molecular 
weight by gel filtration, the elution volume parameter of the protein of interest is 
combined with elution volumes obtained for the standard proteins.  
The proteins of interest have a theoretical molecular weight of 22 kDa and 25 
kDa; thus, the complex should have a molecular weight of about 50 kDa. Before the start 
of the fraction collection, the loop was emptied with 5 ml and the column washed with 0.2 
CVs (≈ 24 ml of Buffer A). Figure 56 shows the chromatogram of the three standard 
proteins detected at 280 nm.  
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Figure 56: Chromatogram of the calibration of the HiLoad 16/60 75 pg size-exclusion 
column. The stock solutions of the calibration kit were diluted to 20 mg/ml as described in the 
manual. 3 mg of ribonuclease A, 4 mg of carbonic anhydrase and 4 mg of ovalbumin were used in 
a total volume of 1 ml (add Buffer A). Proteins were centrifuged at 9.700 rpm for 10 min at 4°C 
before loading via a 2 ml loop. The three standard proteins used for calibration, their molecular 
weight and their retention volume are indicated.   
After the calibration, 1 mg of eIF4GII was loaded together with 2 mg of 
ribonuclease A, which was used as an internal standard (figure 57a).  
As the yield of purified eIF4E was much lower, only 0.5 mg were loaded with 2 
mg of ribonuclease A. The internal standard eluted again at the same elution volume. 
However, the peak of eIF4E (figure 57b) overlaps with some other component that could 
not be detected on the 17.5% SDS gel. Although, the recommendations are to load 1 mg 
of protein, 0.5 mg of eIF4E was sufficient to give an acceptable signal. To ensure the 
comparison between the different runs, the chromatograms obtained for eIF4GII and 
eIF4E (red curve) were overlaid with the chromatogram of the standard proteins (black 
curve) as shown in figure 57. For the overlay of two chromatograms, the ribonuclease 
peak of for example the chromatogram containing eIF4GII was oriented at the 
ribonuclease peak of the standard chromatogram. 
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Figure 57: Overlay of the protein standards with either eIF4GII or eIF4E. (a) 1 mg of eIF4GII 
and 2 mg of ribonuclease A as internal standard were loaded on a 16/60 Hi Load Superdex 75 pg 
column. (b) 0.5 mg of eIF4E and 2 mg of ribonuclease A. The elution volumes are indicated. The 
black graph represents the standard curve, the red graph eIF4GII and eIF4E respectively.  
According to Slepenkov et al., the optimal ratio of eIF4GII:eIF4E for complex 
formation is with equal or lower amounts of eIF4E (Slepenkov et al. 2008). Hence, 
eIF4GII:eIF4E ratios of 1:1, 1:0.5 and 1:0.25 were incubated overnight at 4°C prior to 
size-exclusion chromatography. 0.5 mg of eIF4GII was used with 0.5 mg, 0.25 mg or 
0.125 mg of eIF4E. 2 mg of ribonuclease A was added to each run as internal standard. 
Figure 58 presents the run of the 1:1 ratio of eIF4GII and eIF4E. The ribonuclease A 
peak as well as the peak of eIF4GII are visible at comparable elution volumes as seen in 
figure 57a.  However, no signal for eIF4E could be detected, as none of the peaks would 
be at an equal elution volume as the one shown in figure 57b. Therefore, the formation of 
a complex between eIF4GII and eIF4E could not be demonstrated by size-exclusion. 
The chromatograms of the 1:0.5 and 1:0.25 ratios of eIF4GII:eIF4E are not shown as no 
signal for eIF4E was obtained.  
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Figure 58: Overlay of the protein standards with the chromatogram of the the 1:1 ratio of 
eIF4GII:eIF4E. 0.5 mg of eIF4GII, 0.5 mg of eIF4E and 2 mg of ribonuclease A were loaded on a 
16/60 HiLoad Superdex 75 pg column. The ribonuclease A peak and the peak of eIF4GII are 
indicated as well as their elution volume. The black graph indicates the standard curve, the red 
the curve of eIF4GII:eIF4E in a ratio of 1:1.  
 
4.6.2 Binding to m7 GTP beads 
The second approach to demonstrate complex formation of eIF4GII-eIF4E was by 
using 7-Methyl-GTP Sepharose 4B beads. As described in 3.3.4, the m7GTP beads were 
used to purify eIF4E. In the case of complex formation, eIF4E would bind to m7 GTP of 
the beads and eIF4GII to the bound eIF4E.  
The beads were incubated overnight at 4°C with 500 µl of eIF4E (0.5 µg/µl). 
Unbound eIF4E was washed out with 6 ml of eIF4E binding buffer, as described in 
3.3.4.3 2 ml fractions were collected and examined on a 17.5% SDS gel (data not 
shown). 200 µl eIF4GII (10 µg/µl) were added overnight at 4°C. A large excess of 
eIF4GII was chosen to ensure the binding to eIF4E on the beads. The unbound eIF4GII 
was washed out with 6 ml eIF4E binding buffer (20 mM MOPS pH 7.6, 0.25 mM DTT, 
0.1 mM EDTA, 50 mM NaF and 100 mM KCl) and a 9 µl aliquot of the beads was 
analyzed on a 17.5% SDS gel (figure 59a). To elute eIF4E, the beads were incubated for 
3 h with 600 µl of eIF4E elution buffer at 4°C. After the elution with 10 ml eIF4E elution 
buffer, the beads were regenerated as described in 3.3.4. The 1 ml fractions collected 
during the elution step were examined by SDS PAGE (figure 59b). Most of eIF4GII is 
washed out during the washing step. As the aliquot of the beads contains eIF4E and 
eIF4GII, we assume that wild-type eIF4E indeed binds to the here used eIF4GII fragment 
and builds a complex. Surprisingly, in the elution fractions (E1-E9) only eIF4GII and not 
eIF4E was observed. This might be due to the already low amount of eIF4E shown in the 
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beads aliquot and elution dilutes this even further thus it is no longer visible on the SDS 
PAGE.  
 
Figure 59: Complex formation confirmed using 7-Methyl-GTP Sepharose beads. (a) 9 µl of 
each unbound eIF4GII fraction (2 ml fractions of U1-U4) and 9 µl aliquot of beads with eIF4GII 
and eIF4E before incubation with eIF4E elution buffer. (b) After incubation with 500 µl elution 
buffer, 1 ml elution fractions of eIF4E (E1-E9) were collected. M indicates the Precision Plus 
Protein Standard All Blue from BioRad (12 µl loaded). 
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5 Discussion 
As the leader protease of FMDV is an excellent target for antiviral drugs, the 
investigation of its binding properties is of great importance. The crucial step during the 
production of viable virus particles is the self-processing reaction of Lbpro. During this 
reaction Lbpro frees itself from the viral polyprotein by cleavage between its own C-
terminus and the N-terminus of the capsid protein VP4. The inhibition of the self-
processing event is thought to impair the formation of viable virions. Due to previous 
experiments on the 2A protease of poliovirus (Crowder et al. 2005), Lbpro is considered to 
act similar and remain connected to VP4 which hinders correct capsid formation. Hence, 
an antiviral drug designed to prevent the self-processing of Lbpro is thought to protect 
from FMDV infection.  
Lbpro is known to be a highly specific protease processing only three known 
substrates, the viral polyprotein and the two homologues of eIF4G (eIF4GI eIF4GII). A 
consensus sequence of these cleavage sites cannot be determined due to the strong 
variation amongst them. However, Lbpro was found to prefer Lys at P1 in the viral 
polyprotein whereas Gly is favored in eIF4GI and eIF4GII (Strebel et al. 1986, Foeger et 
al. 2002, Gradi et al. 2004). The main determinant of specificity is the S2 subsite 
comprising a deep hydrophobic pocket accepting only Val, Leu and, to some extent, Ile. 
Surprisingly, a cleavage site in eIF4GII similar to the natural cleavage sequence in 
eIF4GII is not recognized by Lbpro. The presence of Phe at P2 and Asp at P3 at this site 
inhibit cleavage due to sterical hindrance, mainly from Leu143 of the hydrophobic pocket 
(Mayer et al. 2008). The substitution of Leu143 with Ala provides more room in the S2 
pocket and allows Phe to be accepted. Therefore, Leu143 seems to occupy an important 
position in the hydrophobic pocket excluding substrates containing Phe at P2. This 
property is further underlined by the fact that the only other residue found at position 143 
amongst FMDV strains is Met.  
  To gain deeper insight in the binding specificities, a leader protease containing 
the L143A mutation was generated. The mutant protease was then compared to the 
wild-type regarding the cleavage properties on two different eIF4GII fragments. Lbpro 
L143A was expected to recognize additional cleavage sites, thus producing additional 
cleavage products. For the identification of these cleavage sites mass spectrometry 
analysis was chosen. Furthermore, according to Ohlmann et al. 1997 the presence of 
eIF4E improves eIF4G processing by Lbpro. eIF4G is thought to become structured upon 
binding eIF4E thus exposing the Lbpro recognition site. These conformational changes 
may grant better access to the cleavage site for Lbpro. Hence, the differences of cleavage 
in presence and absence of eIF4E were analyzed.  
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5.1 Complex formation of the eIF4GII fragment and eIF4E wild-
type 
Two different approaches were used to examine the binding of the used eIF4GII 
fragment to wild-type human eIF4E. The amino acid sequence of the eIF4GII fragment 
used throughout the thesis is shown in figure 24a.  
A HiLoad 16/60 Superdex 75 prep grade gel filtration column was used to confirm 
the binding of eIF4E to the eIF4GII fragment. Due to physical problems with the column 
itself, some peaks show slight fronting. Nevertheless, ribonuclease A used as an internal 
standard elutes at comparable volumes in all runs as well as the eIF4GII sample and 
eIF4E during the single runs (figures 56 and 57). However, when different amounts of 
eIF4E:eIF4GII were preincubated overnight and loaded on the column, only peaks of 
eIF4GII and ribonuclease A were detectable, as confirmed by SDS PAGE. Even though 
the same amount of eIF4E was used as during the single run (figure 57b), no signal was 
obtained for eIF4E in complex with eIF4GII. The complex of eIF4E-eIF4GII should have 
a molecular weight of about 50 kDa and thus elute earlier than eIF4GII and eIF4E alone. 
No peak at an elution volume earlier than 52 ml was detected suggesting that no 
complex formation occurred or was below detection limit. 
The determination of the molecular weight using size-exclusion chromatography is 
intended for globular proteins with a defined fold as Lbpro wt. eIF4GII was shown to 
contain highly flexible regions and to undergo a unfolded-to-folded transition upon 
binding to the cap binding protein eIF4E (Hershey et al. 1999, Gross et al. 2003). This 
might be one reason that eIF4GII elutes not at the volume expected for a protein of 22 
kDa. According to its theoretical size of 25 kDa, eIF4E would be expected to elute before 
eIF4GII. eIF4GII elutes at about 53 ml whereas eIF4E elutes at about 60 ml. This would 
argue again for partially unstructured region in eIF4GII influencing its elution.   
The manual of the low molecular calibration kit suggests to load 1 mg of the protein 
of choice with 2 mg of an internal standard. As the yield of eIF4E was very low with the 
purification methods used, 1 mg of eIF4E could not be loaded. Consequently, another 
reason that eIF4E was not observed during any run together with eIF4GII might be the 
low amount of protein loaded. The fractions possibly containing protein were analyzed by 
SDS PAGE, but eIF4E was not detected in any run together with eIF4GII.  
Thus, another method was chosen to confirm the interaction of eIF4GII and eIF4E. 
For the second attempt 7-Methyl-GTP Sepharose beads were used. The cap binding 
protein eIF4E binds to 7-Methyl-GTP. Additional eIF4GII thus should bind eIF4E and 
stay bound to the beads via eIF4E. First the beads were incubated with eIF4E overnight. 
After washing out unbound eIF4E, an excess of eIF4GII was added to the beads and 
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again incubated overnight. Following the washout of unbound eIF4GII, an aliquot of the 
beads was taken and analyzed together with the washout on a 17.5% SDS gel (figure 
59a). Most of added eIF4GII was washed out during the washing step. However, some 
eIF4GII seems to stay bound to the beads via eIF4E. However, we cannot exclude that 
still some unbound eIF4GII is present. The separation of the beads aliquot show the 
bands of eIF4GII at 25 kDa and eIF4E at about 37 kDa. Another band at about 33 kDa 
arises from impurities of the eIF4E sample. Interestingly, the fractions collected during 
the elution of eIF4E show only eIF4GII. This might be due to the excess of eIF4GII 
added and the heavy dilution of eIF4E. Nevertheless, the eIF4GII fragment can be 
considered to bind wt eIF4E and thus forming a complex. 
Instead of the eIF4E elution buffer used throughout this experiment, 0.75 µM 
m7GTP can be added to a buffer containing 20 mM Hepes pH 7.6, 0.5 mM DTT, 0.2 mM 
EDTA, 10 % glycerol and 0.5 mM PMSF to elute eIF4E as performed by Zapata et al. 
1993. 0.1 mM GTP can also be used instead of m7GTP. Furthermore, von der Haar et al. 
2000 showed that eIF4E is also eluted using 20 mM GDP. Whether the use of m7GTP, 
GTP or GDP alters the amount of eIF4E after purification or yields a more definite result 
regarding the interaction between eIF4GII-eIF4E is not known. Hence, subsequent 
experiments would be needed to document a difference.  
Similar experiments by Lamphear and colleagues using 7-Methyl-GTP Sepharose 
beads confirmed the interaction of the N-terminal fragment of eIF4GI to eIF4E 
(Lamphear et al. 1995). Subsequent studies by Mader et al. verified these findings 
(Mader et al. 1995). Furthermore, the eIF4GII fragment used throughout this thesis is 
thought to bind full-length eIF4E as comparable fragments of eIF4G were shown to bind 
full length mouse eIF4E (Mader et al. 1995). One prerequisite for efficient binding of 
eIF4G to eIF4E was shown to be the presence of the conserved eIF4E binding motif. 
However, fragments containing this sequence at the very N-terminus did not bind eIF4E. 
In addition, the presence of m7GTP, as present on the 7-Methyl-GTP beads, should 
further enhance the binding affinity of eIF4E to eIF4G.  
Although these findings would argue for the interaction of the eIF4GII fragment 
with full-length human eIF4E, subsequent approaches would be needed to ensure the 
binding. Techniques like Far Western Blot as used in Mader et al. 1995 or other methods 
testing protein-protein interactions as co-immunoprecipitation or two-hybrid screening 
may be performed. However, the fact that unidentified regions important for eIF4E 
interaction might be lacking on the truncated eIF4GII needs to be considered as well.  
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5.2 Processing properties of Lbpro wt and Lbpro L143A on eIF4GII 
Lbpro wt and Lbpro L143A were shown to be active by cleaving eIF4GI/II of HeLa cell 
extracts (figure 38). Consequently, both proteases were incubated with the eIF4GII 
fragment and the cleavage products analyzed. With 50 ng of both proteases, 50% of 
eIF4GII were cleaved after 10 min at 30°C. Furthermore, the kinetics of the cleavage 
reaction were very fast as the major differences are detectable in the first 10 min (figure 
40 and 43).  
As mentioned before, position 143 of the leader protease is important for the 
sustainment of substrate specificity by preventing the cleavage of Phe at P2 sites. By 
mutation of this residue to Ala, more space is provided in the hydrophobic S2 pocket of 
Lbpro. Therefore, Lbpro L143A is expected to cleave additional sites containing Gly at P1 
and Arg or Ser at P1’ as well as the related cleavage sequence in eIF4GII 
(AFADFGXRQTPGG) not recognized by Lbpro wt. Indeed, additional cleavage products 
with Lbpro L143A could be identified (figure 43) and were examined by mass 
spectrometry (figure 45). However, peptides matching for both samples did not give 
concrete information on additional cleavage sites. Interestingly, matches were only found 
for the very N- and C-terminal part of eIF4GII. The related sequence, expected to be 
cleaved by Lbpro L143A, is also part of the peptides found by mass spectrometry. Still, it 
is not clearly distinguishable as additional cleavage site as only parts of the peptide 
which would be generate by cleavage at this sequence were detected by mass 
spectrometry. For exact determination of the cleavage sequences N-terminal sequencing 
might be the method of choice.  
After several processing assays the larger cleavage product became weaker on 
SDS gels. To determine the reason, new aliquots of Lbpro wt and eIF4GII as well as new 
buffer were used. Furthermore, eIF4E and m7GTP were added to the assays as this 
should improve the processing reaction. Neither of these trials could restore the larger 
cleavage product. Furthermore, to determine whether the proteins behave similarly in 
their native state, blue native gel electrophoresis was performed. Besides the processing 
assays, different ratios of the binary complex eIF4GII:eIF4E and the ternary complex 
eIF4GII:eIF4E:m7GTP were loaded to observe potential complex formation. The 10% BN 
PAGE (figure 55) shows that the larger cleavage product is present in amounts 
comparable to the cleavage products observed in figure 39. Hence, eIF4GII seems to be 
in the native state and successfully processed by Lbpro wt. Due to its low percentage of 
the BN-PAGE, the smaller processing product is not detectable. The different ratios of 
eIF4GII:eIF4E with and without m7GTP did not shed light on the formation of the binary 
or ternary complex. As marker, the Precision Plus Protein Standard All Blue from BioRad 
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was loaded on the native gels even though it is recommended for SDS PAGE. Especially 
the marker bands of the 15% gel (data not shown) were not well distinguishable from 
each other, which makes the identification of the potential complex more difficult. 
Consequently, no conclusion concerning the complex of eIF4E-eIF4GII can be drawn 
using BN-PAGE.  
To confirm the interaction between eIF4E and eIF4GII by BN-PAGE subsequent 
trials using different parameters would be necessary. However, the larger cleavage 
product, previously not detectably by SDS PAGE, was observed again in subsequent 
processing assays. The reason for the absence of the larger cleavage product could not 
be determined. 
 
5.3 Processing properties of Lbpro wt and Lbpro L143A on 
eIF4GIIself 
Besides the eIF4GII fragment, another fragment termed eIF4GIIself was used for 
several processing assays. In eIF4GIIself, the wild-type cleavage site of eIF4GII 
LLNVG↓SRRSQ was replaced by QRKLK↓GAGQS. The chemical environment present 
in eIF4GII is different to the one in Lbpro. Therefore, we repeated the processing assays 
with eIF4GIIself as substrate and Lbpro wt or Lbpro L143A. The Lbpro self-processing 
sequence was recognized by both proteases despite the differences in the chemical 
environment (figure 48 and 49). Surprisingly, the amount of both proteases needed to 
cleave 50% of eIF4GIIself was much lower than for eIF4GII. 15 ng of Lbpro wt and 6.25 ng 
of Lbpro L143A were sufficient to process 50% of eIF4GIIself at 30°C for 10 min. Despite 
the fact that the Lbpro self-processing site is not present in wild-type eIF4GII, it is 
recognized with higher efficiency than the wild-type cleavage sequence. This leads to the 
assumption that Lbpro has a greater affinity for the Lbpro self-processing sequence than 
the cleavage sequence present in eIF4GII.  
Santos et al. 2009 examined the hydrolytic activity of Lbpro using peptides derived 
from the self-processing site and the cleavage sites on eIF4GI and eIF4GII. These 
peptides varied in length and sequence to examine the extended Lbpro binding site. 
Subsequent experiments on the processing reactions with different peptides revealed 
that the specificity of Lbpro is mainly determined by the nonprime side and dependent on 
the size of the substrate. Furthermore, Santos and colleagues demonstrated that 
peptides containing cleavage sites of eIF4GI or eIF4GII were poor substrates compared 
to peptides including the self-processing site. An explanation might be that the peptides 
used were missing two binding sites essential for processing by Lbpro. One binding site 
allows the recruitment of eIF4E and the second was shown to be crucial for the binding 
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of the C-terminal extension of Lbpro. The lack of these interactions could explain the poor 
cleavage in the in vitro assay. During my work, eIF4GII fragments containing both sites 
were used. However, my work confirms the results of Santos et al., as the eIF4GII 
fragment comprising the Lbpro self-processing site was cleaved more efficiently as the 
fragment with the natural cleavage site. 
 
5.4 Change of processing properties of Lbpro wt /Lbpro L143A 
using additional eIF4E 
In the course of cap-dependent translation eIF4G together with eIF4E and eIF4A 
forms the translation initiation complex eIF4F. While eIF4E binds the cellular cap of 
mRNA, eIF4G acts as scaffold binding eIF4E, the poly(A) tail and eIF3 which  
coordinates the complex to the 40S ribosomal subunit. Previous experiments 
demonstrated that eIF4G is cleaved more efficiently in the presence of eIF4E as an 
unfolded-to-folded transition of eIF4GII is proposed (Gross et al. 2003). Subsequently, 
the cleavage sequence should become better accessible to the protease enhancing the 
processing efficiency. The conformational changes eIF4G is able to undergo suggests 
that it might have different biochemical properties in the absence of eIF4E (Hershey et 
al. 1999). As most of these experiments displaying the unfolded-to-folded transition were 
only performed with truncated versions of eIF4G, further data on the structure of eIF4G 
in presence and absence of eIF4E is required.  
To test whether the eIF4GII or eIF4GIIself fragment is processed more efficiently, 
eIF4E was added in different ratios to during the processing assays.  
 
5.4.1 Processing of eIF4GII with eIF4E and Lbpro wt/ Lbpro L143A 
 Foremost, processing assays with eIF4GII:eIF4E in ratios of 1:1, 1:2 and 1:3 
were performed using 50 ng of protease (figure 51). However, no significant differences 
between the processing assays with only eIF4GII and those in presence of eIF4E were 
observed. Furthermore, no enhanced cleavage effect can be seen between the different 
amounts of eIF4E added. Interestingly, the larger cleavage product (cpN) in the assay of 
figure 51 runs differently depending on the protease used for cleavage. Lbpro L143A 
seems to produce two larger cleavage products of similar size; one of the same size as 
the cpN generated with Lbpro wt, the other cleavage product slightly smaller. This might 
lead to the conclusion that Lbpro L143A processes the related cleavage sequence 
AFADFG↓RQTPGG found in eIF4GII as well. However, this could not be verified by 
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mass spectrometry and similar assays using eIF4GIIself instead did not show this 
discrepancy.  
 According to Slepenkov et al. 2008 cleavage of eIF4G is improved by adding 
equal or lower amounts of eIF4E to eIF4GII. Therefore, assays with ratios 1:1, 1:0.5 and 
1:0.25 of eIF4GII:eIF4E and 50 ng of the protease were carried out (figure 52). Again, 
the size difference of the larger cleavage product generated with the mutant protease 
was present, but no improvement of cleavage could be detected. Other experiments 
testing the assembly of the 48S complex as in Morino et al. used as well lower amounts 
of eIF4E (0.3 µg) with 2 µg of eIF4G (Morino et al. 2000). This indicates again, that the 
binding of eIF4E to eIF4G prefers lower amounts of eIF4E.  
 Ohlmann et al. proposed that in the case of the leader protease, the eIF4G-eIF4E 
complex is a much better substrate than eIF4G alone (Ohlmann et al. 1997). In contrast 
to HRV2 2Apro which requires the presence of eIF4E for efficient cleavage of eIF4GII, 
Lbpro is able to cleave eIF4G on its own (Haghihat et al. 1996). Furthermore, a 98 amino 
acid region of yeast eIF4G was shown to undergo an unfolded-to-folded transition upon 
binding of eIF4E (Hershey et al. 1999). This region overlaps with the eIF4E binding 
sequence on eIF4G. Gross et al. confirmed these results and demonstrated that also the 
N-terminal region of yeast eIF4E (residues 24-35) becomes structured upon binding 
eIF4G (Gross et al. 2003). In turn, these residues promote the folding of amino acids 
393-490 in yeast eIF4G. In human eIF4GII, the cleavage sequence for Lbpro wt is located 
66 amino acids distant from the conserved eIF4E binding motif. Hence, we speculated 
that the cleavage sequence recognized by Lbpro also becomes structured upon binding of 
eIF4E. Due to the then structured region, the processing reaction might be enhanced as 
the region is better accessible for Lbpro. However, no such effect was observed in any 
processing assay performed with eIF4GII and eIF4E. This might be because the eIF4GII 
fragment used is truncated and contains only the sites necessary for eIF4E binding and 
Lbpro cleavage. As the conformational changes of eIF4G upon binding eIF4E have only 
been demonstrated in yeast so far, human eIF4GII might require additional regions or 
factors to become structured. Hence, further structural investigations on human eIF4G 
are needed to shed light on this process.  
 
5.4.2 Processing of eIF4GIIself with eIF4E and Lbpro wt /Lbpro L143A 
 Processing assays using eIF4GIIself together with eIF4E were performed similar to 
those with eIF4GII. First eIF4E was used in higher ratios shown in figure 57. 6.25 ng of 
Lbpro L143A and 15 ng of Lbpro wt were used for the processing assay of eIF4GIIself as 
these amounts were shown to process 50% of eIF4GIIself after 10 min at 30°C. However, 
 94 
with an excess of eIF4E no significant difference in cleavage was observed. Therefore, 
the amount of eIF4E was lowered and ratios of 1:1, 1:0.5 and 1:0.25 of eIF4GIIself:eIF4E 
were used. Again, no improvement of the cleavage ability of was identified. The different 
size of the larger cleavage product, as seen in processing assays of eIF4GII-eIF4E with 
both proteases, is not seen with eIF4GIIself as substrate. However, Lbpro L143A clearly 
generates an additional cleavage product running at about 16 kDa which is not seen with 
Lbpro wt. 
 
5.4.3 Processing of eIF4GII with eIF4E and m7GTP 
According to Niedzwiecka et al. 2002, eIF4G binding to eIF4E enhances the 
ability of eIF4E to interact with the mRNA 5’ cap-structure and vice versa. Due to this 
suggestion 100 µM m7GTP were added to the processing assay containing 
eIF4GII:eIF4E in different ratios. This experiment was mainly performed to restore the 
larger cleavage product, which was observed to become weaker on SDS PAGE in 
several assays. No change in the processing pattern was recognizable. This might 
indicate that more m7GTP may be needed to observe an improved cleavage of eIF4GII. 
 
5.5 Conclusion 
The development of antiviral drugs is an important field of research not only 
regarding FMDV but also many other human and animal pathogens. In FMDV the leader 
protease is considered an optimal target for antiviral drugs. Previous experiments 
demonstrated that the inhibition of Lbpro activity in cells causes a 1000-fold reduction in 
virus yield (Kleina et al. 1992). In addition, investigations on the 2Apro of PV1 showed that 
if 2Apro is inhibited, it remains connected to VP1 thus preventing the formation of viable 
virus (Crowder et al. 2005). These findings are thought to be also adoptable for Lbpro of 
FMDV.  
To design a functional inhibitor, information about the specificity and possible 
interactions of Lbpro with substrates are necessary as is also the X-ray crystal structure. 
Several experiments indicate that Leu143 of Lbpro is crucial for the maintenance of 
specificity. Leu143 is located in the S2 pocket and prevents cleavage of substrates 
containing Phe at the P2 position due to sterical hindrance. However, replacement of 
Leu143 by Ala provides more space and was shown to accept Phe (Mayer et al. 2008).  
Therefore, a Lbpro containing the L143A mutation was generated. As substrates, 
two different human eIF4GII fragments were used (aa 552-745). One, termed eIF4GII, 
contained the natural cleavage site recognized by Lbpro. In the second fragment, 
 95 
eIF4GIIself, the natural recognition sequence was replaced by the Lbpro self-processing 
site. The different specificities were observed using Lbpro wt and Lbpro L143A with both 
substrates in processing assays. In the case of eIF4GII, 50 ng of both proteases were 
needed to process 50% of eIF4GII. In contrast, 15 ng of Lbpro wt and 6.25 ng of Lbpro 
L143A were sufficient for 50% cleavage of eIF4GIIself. The lower amount of protease 
needed to cleave eIF4GIIself suggests that the Lbpro self-processing site might be 
recognized more efficiently despite the different chemical environment present in 
eIF4GII. Additionally, Lbpro L143A generated aberrant processing products due to its 
lower specificity. However, analysis by mass spectrometry of two additional cleavage 
products did not reveal further cleavage sites recognized by Lbpro L143A. To determine 
putative cleavage sites recognized by Lbpro L143A, another method might be more 
effective.  
In several processing assays eIF4E was added to eIF4GII. According to Gross et 
al. 2003, eIF4G undergoes an unfolded-to-folded transition upon binding to eIF4E. We 
hypothesize that also the recognition site for Lbpro becomes more structured and exposed 
which might facilitate the cleavage by Lbpro. Therefore, processing assays with 
supplementary eIF4E are thought to enhance the cleavage properties of Lbpro. However, 
no significant difference in processing, neither with Lbpro wt nor with Lbpro L143A, was 
observed by adding eIF4E to the assays. This could be due to the use of human eIF4G 
and eIF4E, as most studies on enhanced processing were done in yeast (Hershey et al. 
1999). A second explanation might be that the eIF4GII fragments are lacking certain 
unidentified regions important for eIF4E interaction and processing by Lbpro.   
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6 Appendix 
6.1 Abbreviations 
4E-BP    4E-binding protein  
aa    Amino acids 
Amp    Ampicillin 
BN PAGE   Blue native gel electrophoresis 
Cam    Chloramphenicol 
CIP    Calf intestine phosphatase 
cre    Cis-acting RNA replication element 
CTE    C-terminal extension 
DNA    Deoxyribonucleic acid 
DTT    Dithiothreitol 
EDTA    Ethylenediaminetetraacetic acid 
eIF3    Eukaryotic initiation factor 3 
eIF4A    Eukaryotic initiation factor 4A 
eIF4E    Eukaryotic initiation factor 4E 
eIF4F    Eukaryotic initiation factor 4F 
eIF4G    Eukaryotic initiation factor 4GI / 4GII 
FMDV    Foot-and-mouth disease virus  
GDP    Guanosine dipohsphate 
GTP    Guanosine triphosphate 
HEAT Huntingtin, elongation factor 3, protein phosphatase 2A and 
yeast PI3 kinase TOR1 
HAV    Hepatitis A virus 
HeLa    Henrietta Lacks’ cells 
HRV    Human rhinovirus 
ICAM-1   Intercellular adhesion molecule 1 
ICTV    International committee on taxonomy of viruses 
IFN    Interferon 
IRES    Internal ribosomal entry segment 
kDa    Kilo Dalton  
LB    Luria Bertani 
Labpro    Leader protease ab 
Lbpro    Leader protease b 
mRNA    Messenger RNA 
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NF-κB    Nuclear factor kappa B 
NMR    Nuclear magnetic resonance 
ORF    Open reading frame 
PABP    Poly-A binding protein  
PV    Poliovirus 
RGD    Arg-Gly-Asp 
RNA    Ribonucleic acid  
RNP Ribonucleoprotein 
SDS PAGE Sodiumdodecylsulfate Polyacrylamide Gel electrophoresis 
TAE    Tris-acetate-EDTA 
TE    Tris-EDTA 
UTR    Untranslated region 
UV    Ultra-violet 
VP1-VP4   Viral protein 1-4  
VPg    Viral protein genome linked 
wt    Wild-type 
6.2 List of amino acids 
G Gly Glycine 
A Ala Alanine 
V Val Valine 
L Leu Leucine 
I Ile Isoleucine 
M Met Methionine 
P Pro Proline 
S Ser Serine 
T Thr Threonine 
C Cys Cysteine 
H His Histidine 
F Phe Phenylalanine 
Y Tyr Tyrosine 
W Trp Tryptophane 
N Asn Asparagine 
Q Gln Glutamine 
D Asp Aspartate 
E Glu Glutamate 
K Lys Lysine 
R Arg Arginine 
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PERSÖNLICHE INFORMATIONEN 
 
GEBURTSDATUM    29.02.1984 
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1994-1996    Gymnasium in Wien (Amerlinggymnasium) 
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